U.S. patent application number 14/190884 was filed with the patent office on 2014-10-02 for use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide.
This patent application is currently assigned to SENESCO TECHNOLOGIES, INC.. The applicant listed for this patent is Richard S. Dondero, Catherine A. Taylor, John E. Thompson. Invention is credited to Richard S. Dondero, Catherine A. Taylor, John E. Thompson.
Application Number | 20140296320 14/190884 |
Document ID | / |
Family ID | 41065784 |
Filed Date | 2014-10-02 |
United States Patent
Application |
20140296320 |
Kind Code |
A1 |
Dondero; Richard S. ; et
al. |
October 2, 2014 |
Use Of siRNA To Achieve Down Regulation Of An Endogenous Gene In
Combination With The Use of A Sense Construct To Achieve Expression
Of A Polynucleotide
Abstract
The present invention relates to the combinatorial use of an
siRNA targeted against an endogenous gene to knock out or knock
down expression of the endogenous gene in a host and a delivery of
a polynucleotide encoding the gene in a delivery vehicle/expression
vector to the host to provide expression in the host of the protein
encoded by the polynucleotide.
Inventors: |
Dondero; Richard S.;
(Riverdale, NJ) ; Thompson; John E.; (Waterloo,
CA) ; Taylor; Catherine A.; (Waterloo, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Dondero; Richard S.
Thompson; John E.
Taylor; Catherine A. |
Riverdale
Waterloo
Waterloo |
NJ |
US
CA
CA |
|
|
Assignee: |
SENESCO TECHNOLOGIES, INC.
New Brunswick
NJ
|
Family ID: |
41065784 |
Appl. No.: |
14/190884 |
Filed: |
February 26, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12400742 |
Mar 9, 2009 |
8703929 |
|
|
14190884 |
|
|
|
|
61034830 |
Mar 7, 2008 |
|
|
|
Current U.S.
Class: |
514/44A ;
435/320.1 |
Current CPC
Class: |
C12N 15/85 20130101;
C12N 2320/31 20130101; A61K 48/0008 20130101; C12N 2310/14
20130101; A61P 35/00 20180101; C12N 15/113 20130101; C12N 15/88
20130101; C07K 14/4702 20130101 |
Class at
Publication: |
514/44.A ;
435/320.1 |
International
Class: |
C12N 15/113 20060101
C12N015/113; C12N 15/85 20060101 C12N015/85 |
Claims
1. A composition comprising a complex of an eIF5A1 siRNA targeted
against the 3' end of eIF5A1, an expression vector comprising a
polynucleotide encoding a mutant eIF5A1 wherein the mutant eIF5A1
is unable to be hypusinated, and wherein the siRNA and the
expression vector are complexed to polyethylenimine to form a
complex.
2. A composition comprising an siRNA targeted against a target gene
to suppress endogenous expression of the target gene in a subject;
and a polynucleotide encoding a target protein capable of being
expressed in the subject in an RNAI resistant plasmid, wherein the
siRNA and the plasmid are complexed to polyethylenimine to form a
complex.
3. The composition of claim 1 wherein the siRNA has the sequence
shown in FIG. 25 and wherein the polynucleotide encoding the mutant
eIF5A1 is eIF5A1.sup.K50R.
4. The composition of claim 3 comprising a tissue specific
promoter.
5. The composition of claim 4 comprising a B cell specific
promoter.
6. The composition of claim 5 wherein the B cell promoter is
B29.
7. The composition of claim 3 wherein the expression vector
comprises a pCpG plasmid.
8. The composition of claim 1 wherein the eIF5A1 siRNA and the
expression vector comprising the mutant eIF5A1 polynucleotide are
independently complexed to polyethylenimine.
9. The composition of claim 1 wherein the eIF5A1 siRNA and the
expression vector comprising the mutant eIF5A1 polynucleotide are
together complexed to polyethylenimine.
10. A composition comprising an eIF5A1 siRNA targeted against the
3' end of eIF5A1 and an expression vector comprising a
polynucleotide encoding a mutant eIF5A1 wherein the mutant eIF5A1
is unable to be hypusinated, and wherein the siRNA and the
expression vector are delivered to a subject to treat cancer.
11. The composition of claim 10, wherein the cancer is multiple
myeloma.
12. A method of treating cancer comprising administering the
composition of claim 10 to a subject.
13. A method of treating cancer comprising administering the
composition of claim 1 to a subject.
14. The method of claim 12 wherein the composition is administered
intravenously, intra peritoneally or intra tumorally.
15. The method of claim 13 wherein the siRNA targeted against the
3' end of eIF5A1 and the expression vector comprising the
polynucleotide encoding a mutant eIF5A1 are delivered via different
routes.
16. The method of claim 12 wherein the composition is provided at a
dose of about 0.15 mg/kg to about 1.5 mg/kg for twice weekly
injections.
17. The method of claim 12 wherein the composition is provided at a
dose of about 0.75 mg/kg to about 1.5 mg/kg for twice weekly
injections.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to the combinatorial use of
siRNA targeted against a gene to knock down or knock out expression
of the endogenous gene, and use of a polynucleotide encoding a
exogenous gene to affect expression of that gene.
BACKGROUND OF THE INVENTION
[0002] Relatively recently, researchers observed that double
stranded RNA ("dsRNA") could be used to inhibit protein expression.
This ability to silence a gene has broad potential for treating
human diseases, and many researchers and commercial entities are
currently investing considerable resources in developing therapies
based on this technology.
[0003] Double stranded RNA induced gene silencing can occur on at
least three different levels: (i) transcription inactivation, which
refers to RNA guided DNA or histone methylation; (ii) siRNA induced
mRNA degradation; and (iii) mRNA induced transcriptional
attenuation.
[0004] It is generally considered that the major mechanism of RNA
induced silencing (RNA interference, or RNAi) in mammalian cells is
mRNA degradation. Initial attempts to use RNAi in mammalian cells
focused on the use of long strands of dsRNA. However, these
attempts to induce RNAi met with limited success, due in part to
the induction of the interferon response, which results in a
general, as opposed to a target-specific, inhibition of protein
synthesis. Thus, long dsRNA is not a viable option for RNAi in
mammalian systems.
[0005] More recently it has been shown that when short (18-30 bp)
RNA duplexes are introduced into mammalian cells in culture,
sequence-specific inhibition of target mRNA can be realized without
inducing an interferon response. Certain of these short dsRNAs,
referred to as small inhibitory RNAs ("siRNAs"), can act
catalytically at sub-molar concentrations to cleave greater than
95% of the target mRNA in the cell. A description of the mechanisms
for siRNA activity, as well as some of its applications are
described in Provost et al. (2002) Ribonuclease Activity and RNA
Binding of Recombinant Human Dicer, EMBO J. 21(21): 5864-5874;
Tabara et al. (2002) The dsRNA Binding Protein RDE-4 Interacts with
RDE-1, DCR-1 and a DexH-box Helicase to Direct RNAi in C. elegans,
Cell 109(7):861-71; Ketting et al. (2002) Dicer Functions in RNA
Interference and in Synthesis of Small RNA Involved in
Developmental Timing in C. elegans; Martinez et al.,
Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi,
Cell 110(5):563; Hutvagner & Zamore (2002) A microRNA in a
multiple-turnover RNAi enzyme complex, Science 297:2056.
[0006] From a mechanistic perspective, introduction of long double
stranded RNA into plants and invertebrate cells is broken down into
siRNA by a Type III endonuclease known as Dicer. Sharp, RNA
interference--2001, Genes Dev. 2001, 15:485. Dicer, a
ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base
pair short interfering RNAs with characteristic two base 3'
overhangs. Bernstein, Caudy, Hammond, & Hannon (2001) Role for
a bidentate ribonuclease in the initiation step of RNA
interference, Nature 409:363. The siRNAs are then incorporated into
an RNA-induced silencing complex (RISC) where one or more helicases
unwind the siRNA duplex, enabling the complementary antisense
strand to guide target recognition. Nykanen, Haley, & Zamore
(2001) ATP requirements and small interfering RNA structure in the
RNA interference pathway, Cell 107:309. Upon binding to the
appropriate target mRNA, one or more endonucleases within the RISC
cleaves the target to induce silencing. Elbashir, Lendeckel, &
Tuschl (2001) RNA interference is mediated by 21- and 22-nucleotide
RNAs, Genes Dev. 15:188, FIG. 1.
[0007] The interference effect can be long lasting and may be
detectable after many cell divisions. Moreover, RNAi exhibits
sequence specificity. Kisielow, M. et al. (2002) Isoform-specific
knockdown and expression of adaptor protein ShcA using small
interfering RNA, J. Biochem. 363:1-5. Thus, the RNAi machinery can
specifically knock down one type of transcript, while not affecting
closely related mRNA. These properties make siRNA a potentially
valuable tool for inhibiting gene expression and studying gene
function and drug target validation. Moreover, siRNAs are
potentially useful as therapeutic agents against: (1) diseases that
are caused by over-expression or misexpression of genes; and (2)
diseases brought about by expression of genes that contain
mutations.
[0008] Successful siRNA-dependent gene silencing depends on a
number of factors. One of the most contentious issues in RNAi is
the question of the necessity of siRNA design, i.e., considering
the sequence of the siRNA used. Early work in C. elegans and plants
circumvented the issue of design by introducing long dsRNA (see,
for instance, Fire, A. et al. (1998) Nature 391:806-811). In this
primitive organism, long dsRNA molecules are cleaved into siRNA by
Dicer, thus generating a diverse population of duplexes that can
potentially cover the entire transcript. While some fraction of
these molecules are non-functional (i.e., induce little or no
silencing) one or more have the potential to be highly functional,
thereby silencing the gene of interest and alleviating the need for
siRNA design. Unfortunately, due to the interferon response, this
same approach is unavailable for mammalian systems. While this
effect can be circumvented by bypassing the Dicer cleavage step and
directly introducing siRNA, this tactic carries with it the risk
that the chosen siRNA sequence may be non-functional or
semi-functional.
[0009] A number of researches have expressed the view that siRNA
design is not a crucial element of RNAi. On the other hand, others
in the field have begun to explore the possibility that RNAi can be
made more efficient by paying attention to the design of the
siRNA.
[0010] To treat various diseases or disorders, the upregulation of
certain proteins is desirable but this may not be all that is
needed. For example, the combinatorial use of siRNA to knock down
or knock out expression of an endogenous protein or a different
protein may be needed. The present invention fulfills this need and
provides methods of treating cancer, especially multiple
myeloma.
[0011] Cancer, including multiple myeloma are diseases which would
benefit from the ability to induce apoptosis. Conventional
therapies for of multiple myeloma include chemotherapy, stem cell
transplantation, high-dose chemotherapy with stem cell
transplantation, and salvage therapy. Chemotherapies include
treatment with Thalomid.RTM. (thalidomide), bortezomib, Aredia.RTM.
(pamidronate), steroids, and Zometa.RTM. (zoledronic acid). However
many chemotherapy drugs are toxic to actively dividing
non-cancerous cells, such as of the bone marrow, the lining of the
stomach and intestines, and the hair follicles. Therefore,
chemotherapy may result in a decrease in blood cell counts, nausea,
vomiting, diarrhea, and loss of hair.
[0012] Conventional chemotherapy, or standard-dose chemotherapy, is
typically the primary or initial treatment for patients with of
multiple myeloma. Patients also may receive chemotherapy in
preparation for high-dose chemotherapy and stem cell transplant.
Induction therapy (conventional chemotherapy prior to a stem cell
transplant) can be used to reduce the tumor burden prior to
transplant. Certain chemotherapy drugs are more suitable for
induction therapy than others, because they are less toxic to bone
marrow cells and result in a greater yield of stem cells from the
bone marrow. Examples of chemotherapy drugs suitable for induction
therapy include dexamethasone, thalidomide/dexamethasone, VAD
(vincristine, Adriamycin.RTM. (doxorubicin), and dexamethasone in
combination), and DVd (pegylated liposomal doxorubicin (Doxil.RTM.,
Caelyx.RTM.), vincristine, and reduced schedule dexamethasone in
combination).
[0013] The standard treatment for of multiple myeloma is melphalan
in combination with prednisone (a corticosteroid drug), achieving a
response rate of 50%. Unfortunately, melphalan is an alkylating
agent and is less suitable for induction therapy. Corticosteroids
(especially dexamethasone) are sometimes used alone for multiple
myeloma therapy, especially in older patients and those who cannot
tolerate chemotherapy. Dexamethasone is also used in induction
therapy, alone or in combination with other agents. VAD is the most
commonly used induction therapy, but DVd has recently been shown to
be effective in induction therapy. Bortezomib has been approved
recently for the treatment of multiple myeloma, but it is very
toxic. However, none of the existing therapies offer a significant
potential for a cure. Thus, there still remains a need to find a
suitable treatment for cancer and multiple myeloma. The present
invention fulfills this need.
SUMMARY OF INVENTION
[0014] The present invention relates to the combinatorial use of an
siRNA targeted against an endogenous gene to knock out or knock
down expression of the endogenous gene in a host and a delivery of
a polynucleotide encoding the gene in a delivery vehicle/expression
vector to the host to provide expression in the host of the protein
encoded by the polynucleotide. A polynucleotide encoding a normal
(non faulty) protein (or the protein itself) is administered to the
host and is expressed (in the case of the polynucleotide) so that
the normal protein can perform its necessary function. The siRNA is
preferably designed to target a region of the gene so it either
knocks down or knocks out endogenous expression of the faulty
protein but at the same time will not effect exogenous expression
of the administered polynucleotide encoding the normal protein.
[0015] The invention provides a composition comprising a complex of
an eIF5A1 siRNA targeted against the 3' end of eIF5A1, an
expression vector comprising a polynucleotide encoding a mutant
eIF5AI wherein the mutant eIF5A1 is unable to be hypusinated, and
wherein the siRNA and the expression vector are complexed to
polyethylenimine to form a complex.
[0016] The invention provides a composition comprising an siRNA
targeted against a target gene to suppress endogenous expression of
the target gene is a subject, and a polynucleotide encoding a
target protein capable of being expressed in the subject. In
certain embodiments the polynucleotide is in RNAI resistant plasmid
(will not be suppressed by the siRNA). The siRNA and the plasmid
are preferably complexed to polyethylenimine to form a complex.
[0017] In certain embodiments the siRNA has the sequence shown in
FIG. 25 and wherein the polynucleotide encoding the mutant eIF5A1
is eIF5A1.sup.K50R. The expression vector comprises the a
polynucleotide encoding a mutant eIF5A1 and a promoter operably
linked to provide expression of the polynucleotide in a subject.
The promoter preferably is either tissue specific or systemic. For
example, if the composition is used to treat cancer, then
preferably the promoter is tissue specific for the tissue in which
the cancer resides. For example, for treating multiple myeloma, it
is preferable to use a B cell specific promoter, such as B29. In
certain embodiments, the expression vector comprises a pCpG
plasmid.
[0018] In certain embodiments, the eIF5A1 siRNA and the expression
vector comprising the mutant eIF5A1 polynucleotide are
independently complexed to polyethylenimine, such as in vivo
JetPEI.TM.. In other embodiments, the eIF5A1 siRNA and the
expression vector comprising the mutant eIF5A1 polynucleotide are
complexed together to polyethylenimine.
[0019] The present invention further provides a composition
comprising an eIF5A1 siRNA targeted against the 3' end of eIF5A1
and an expression vector comprising a polynucleotide encoding a
mutant eIF5A1 wherein the mutant eIF5A1 is unable to be
hypusinated, and wherein the siRNA and the expression vector are
delivered to a subject to treat cancer. The cancer may be any
cancer including multiple myeloma.
[0020] The present invention further provides a method of treating
cancer comprising administering composition of the present
invention to a subject (including but not limited to mammals and
humans).
[0021] The composition may be adminstered any acceptable route,
such as, but not limited to intravenously, intra peritoneally,
subcutaneously or intra tumorally. The siRNA and the expression
vector may be administered at different times and via different
routes or may be administered together at the same time and via the
same route. For example, but not limited to, the siRNA may be
delivered naked or complexed to a carrier such as in vivo jetPEI
via IV and the expression vector may be administered intra
tumorally, or both the siRNA and the expression vector may be
administered IV or intratumorally, etc.
[0022] The present invention provides a method of inhibiting cancer
cell growth and/or killing cancer cells. The present invention also
provides a method of inhibiting or slowing down the ability of a
cancer cell to metastasize. Inhibiting cancer growth includes a
reduction in the size of a tumor, a decrease in the growth of the
tumor, and can also encompass a complete remission of the tumor.
The cancer can be any cancer or tumor, including but not limited to
colon cancer, colorectal adenocarcinoma, bladder carcinoma,
cervical adenocarcinoma, and lung carcinoma. Preferably the cancer
is multiple myeloma.
[0023] In preferred embodiments, the eIF-5A is a mutant that is
unable to be hypusinated. Exemplary mutants are described
herein.
[0024] In addition to providing eIF-5A or a polynucleotide encoding
eIF-5A to a subject (to provide expression of the eIF-5A), siRNA is
provided to knock out or knock down endogenous expression of
eIF-5A.
[0025] The present invention also provides the use of eIF5A,
polynucleotides encoding eIF5A1 and siRNA against eIF5A1 to make a
medicament to treat acner kill multiple myeloma cells in a subject
having multiple myeloma. Preferably the polynucleotides encoding a
mutant eIF-5A are unable to be hypusinated.
[0026] The present invention also provides a method of treating
sickle cell anemia. A polynucleotide encoding a healthy hemoglobin
gene (such as HBB) is administered to a patient suffering from
sickle cell anemia. In conjunction, the patient is also
administered siRNA that targets the gene encoding the faulty
hemoglobin gene (such as the gene encoding the mutant HbS) to knock
down or knock out expression of the faulty protein.
[0027] The treatment may further comprise administration of other
known medicines or treatments commonly used in treating sickle cell
anemia.
BRIEF DESCRIPTION OF THE FIGURES
[0028] FIG. 1 provides the amino acid sequence of human eIF-5A1 and
shows various important sites.
[0029] FIGS. 2A and 2B show that mutation of eIF-5A1 at K50 and K67
increases accumulation of transfected protein. See example 1.
[0030] FIG. 3 shows that mutation of eIF5A1 at K47, K50 and K67
increases accumulation of transfected protein. See example 2.
[0031] FIG. 4 shows that mutation of eIF5A1 at K50 and K67 results
in induction of apoptosis when transfected into KAS cells. See
example 3.
[0032] FIG. 5 shows that mutation of eIF5A1 at K50 and K67 results
in induction of apoptosis when transfected into KAS cells. See
example 4.
[0033] FIG. 6 shows that mutation of eIF5A1 at K50 and K67 results
in induction of apoptosis when transfected into KAS cells. See
example 5.
[0034] FIG. 7A shows transfection with siRNA and treating with an
adenovirus that is modified to express eIF-5A1 results in apoptosis
in KAS cells. See example 6A. FIG. 7B shows that pre-treatment with
eIF5A1 siRNA (against target #1 (SEQ ID NO:1)) the sequence of the
siRNA construct shown in FIG. 25 reduced expression of endogenous
eIF5A1 but allows accumulation of RNAi-resistant eIF5A1.sup.k50A
expressed by adenovirus. See example 6B. FIG. 7C shows that
pre-treatment with eIF5A1 siRNA against target #1 prior to
adenovirus infection reduces expression of phosphorylated
NF-.kappa.B in human multiple myeloma cells. See example 6C. FIG.
7D shows that pre-treatment with eIF5A1 siRNA against target #1
prior to Adenovirus infection reduces expression of phosphorylated
NF-kB and ICAM-1 in human multiple myeloma cells. See example 6D.
FIG. 7E shows that siRNA-mediated suppression of eIF5A in human
multiple myeloma cells inhibits LPS-mediated induction of NFkB
DNA-Binding Activity. The inhibition of NFkB activity by eIF5A
siRNA could explain it's ability to increase apoptosis induction
when combined with over-expression of eIF5A.sup.K50R since NF-kB
regulates many pro-survival and anti-apoptosis pathways. FIG. 7F
shows that pretreatment of KAS cells with siRNA increases apoptosis
by eIF5A1.sup.k50R gene delivery in the presence of IL-6. See
example 6E.
[0035] FIG. 8 shows that co-administration of eIF5A1 plasmid and
eIF5A1 siRNA delays growth of multiple myeloma subcutaneous
tumours. The data shown is the tumor volume for all the mice in
each group. See example 7.
[0036] FIG. 9 shows that co-administration of eIF5A1 plasmid and
eIF5A1 siRNA delays growth of multiple myeloma subcutaneous
tumours. The data shown is the average tumor volume per group
+/-standard error. See example 7.
[0037] FIG. 10 shows that co-administration of eIF5A1 plasmid and
eIF5A1 siRNA reduces weight of multiple myeloma subcutaneous
tumours. See example 7.
[0038] FIG. 11 shows that co-administration of eIF5A1 plasmid and
eIF5A1 siRNA delays growth of multiple myeloma subcutaneous tumours
and results in tumour shrinkage. See Example 8.
[0039] FIG. 12 shows that administration of eIF5A1 siRNA
intra-venously (i.v.) and PEI/eIF5A1K50R plasmid complexes
intra-tumourally (i.t.) results in tumour shrinkage of multiple
myeloma subcutaneous tumours. See example 9.
[0040] FIG. 13A shows that treatment with eIF5A1 plasmid and eIF5A1
siRNA delays growth of multiple myeloma subcutaneous tumours and
results in tumour shrinkage. FIG. 13B shows that co-administration
of eIF5A1 plasmid and eIF5A1 siRNA results in tumour shrinkage.
FIG. 13C shows that administration of eIF5A1 siRNA intra-venously
(i.v.) and PEI/eIF5A1.sup.K50R plasmid complexes intra-tumourally
(i.t.) results in tumour shrinkage of multiple myeloma subcutaneous
tumours.
[0041] FIG. 14 shows that intra-venous co-administration of eIF5A1
plasmid and eIF5A1 siRNA delays growth of multiple myeloma
subcutaneous tumours. See example 10.
[0042] FIG. 15 shows that administration of eIF5A1 siRNA
intra-venously (i.v.) and 5 PEI/eIF5A1K5OR plasmid complexes
intra-venously (i.v.) or intra-peritoneal (i.p.) delays growth of
multiple myeloma subcutaneous tumours. See example 11.
[0043] FIG. 16 shows that treatment with eIF5A1 plasmid and eIF5A1
siRNA delays growth of multiple myeloma subcutaneous tumours.
[0044] FIGS. 17A and 17B show that co-administration of eIF5A1
plasmid and eIF5A1 siRNA delays growth of multiple myeloma
subcutaneous tumours and results in tumour shrinkage. See example
12.
[0045] FIGS. 18A and 18B show that administration of eIF5A1 siRNA
intra-venously (i.v.) and PEI/eIF5A1K5OR plasmid complexes
intra-tumourally (i.t.) results in tumour shrinkage of multiple
myeloma subcutaneous tumours. See example 13.
[0046] FIG. 19 shows co-administration of eIF5A1.sup.K50R plasmid,
driven by either the EF1 or B29 promoter, and eIF5A1 siRNA delays
growth of multiple myeloma subcutaneous tumours and results in
tumour shrinkage (KAS-SQ-5). See example 14.
[0047] FIG. 20 shows co-administration of eIF5A1 siRNA increases
anti-tumor effect of eIF5A1.sup.K50R plasmid, driven by either the
EF1 or B29 promoter, on multiple myeloma subcutaneous tumours and
results in reduced tumor burden (KAS-SQ-5). See example 15.
[0048] FIG. 21 shows eIF5A1 siRNA synergistically increases
apoptosis resulting from infection with Ad-eIF5A in lung
adenocarcinoma cells. See example 16.
[0049] FIG. 22 shows the map of pExp5A, the construction of which
is described in Example 17.
[0050] FIGS. 23A and 23 B show the predicted sequence of pExp5A
(3371 bp). See example 17.
[0051] FIGS. 24A and 24B show the rexpression of eIF5A.sup.K50R in
various cell lines. See example 18.
[0052] FIG. 25 shows the target sequence and the sequence of a
preferred eIF5A1 siRNA.
[0053] FIG. 26 provides the results of efficacy studies in multiple
myeloma. See example 21.
[0054] FIG. 27 provides the results of efficacy studies in multiple
myeloma. See example 21.
[0055] FIG. 28 provides the sequence of eIF5A1.sup.K50R cDNA.
[0056] FIG. 29 provides the alignment of human eIF-5A against human
eIF5A.sup.K50R.
[0057] FIG. 30 shows the effect of DNA:siRNA ratio on
HA-eIF5A1.sup.K50R expression. See example 23.
[0058] FIG. 31 shows the effect of DNA:siRNA ratio on apoptosis
induced by nanoparticle transfection. See example 24.
[0059] FIG. 32 shows administration of PEI complexes (N/P=6 or 8)
containing eIF5A1K5OR plasmid and eIF5A1 siRNA (siSTABLE or
non-siSTABLE) inhibits growth of multiple myeloma subcutaneous
tumours and results in tumour shrinkage. See example 25.
[0060] FIG. 33 shows that the JET PEI.TM. nanoparticles are being
effectively taken up by tumour tissue and that nanoparticles are
delivering plasmid and siRNA to the same cell. See example 26.
DETAILED DESCRIPTION OF THE INVENTION
[0061] The present invention relates to the combinatorial use of an
siRNA targeted against an endogenous gene to knock out or knock
down expression of the endogenous gene in a subject and a of a
polynucleotide encoding the gene in a delivery vehicle/expression
vector provided to the subject to provide expression in the host of
the protein encoded by the polynucleotide.
[0062] This combination is useful in treating a subject with a
disease or condition caused by the existence of a faulty or mutant
protein, i.e. where the protein produced in the subject is unable
to perform it necessary function or alternatively, fowls up a
metabolic pathway or biomolecule interaction because of its faulty
structure. The siRNA is designed to target the gene encoding the
faulty protein, and knock down or knock out expression of that
faulty protein. A polynucleotide encoding a normal (non faulty)
protein is administered to the subject and is expressed in the
subject so that the normal protein is available to perform its
necessary function.
[0063] In another embodiment, instead of administering the
polynucleotide encoding the desired protein, the protein is
administered to the subject. The terms protein, peptide and
polypeptide are used herein interchangeably.
[0064] The siRNA is preferably designed to target a certain region
of the gene so it either knocks down or knocks out endogenous
expression of the faulty protein but at the same time will not
effect exogenous expression of the administered polynucleotide
encoding the normal protein. For example, the siRNA may target the
3'UTR so it does not effect exogenous expression of the
administered sense construct (the polynucleotide encoding the
protein). By knocking down or knocking out endogenous expression of
the faulty gene, there will be less or none of the faulty protein
to compete with the normal protein expressed from the exogenous
polynuclecotide.
[0065] One example of a disease state where this application would
be useful concerns sickle cell anemia. Sickle cell anemia is a
blood disorder that affects hemoglobin, the protein found in red
blood cells (RBCs) that helps carry oxygen throughout the body.
[0066] Sickle cell anemia occurs when a person inherits two
abnormal genes (one from each parent) that results in expression of
a mutant hemoglobin (Hbs). The mutant hemoglobin causes the RBCs to
change shape. Red blood cells with normal hemoglobin (hemoglobin A,
or HbA) move easily through the bloodstream, delivering oxygen to
all of the cells of the body. They can easily "squeeze" through
even very small blood vessels. Sickle cell anemia occurs because
the abnormal form of hemoglobin (HbS) tends to clump together,
making red blood cells sticky, stiff, and more fragile, and causing
them to form into a curved, sickle shape.
[0067] Although several hundred HBB gene variants are known, sickle
cell anemia is most commonly caused by the hemoglobin variant HbS.
In this variant, the hydrophobic amino acid valine takes the place
of hydrophilic glutamic acid at the sixth amino acid position of
the HBB polypeptide chain. This substitution creates a hydrophobic
spot on the outside of the protein structure that sticks to the
hydrophobic region of an adjacent hemoglobin molecule's beta chain.
This clumping together (polymerization) of HbS molecules into rigid
fibers causes the "sickling" of red blood cells.
[0068] Polymerization occurs only after red blood cells have
released the oxygen molecules that they carry to various tissues
throughout the body. Once red blood cells return to the lungs where
hemoglobin can bind oxygen, the long fibers of HbS molecules
depolymerize or break apart into single molecules. Cycling between
polymerization and depolymerization causes red blood cell membranes
to become rigid. The rigidity of these red blood cells and their
distorted shape when they are not carrying oxygen can result in
blockage of small blood vessels. This blockage can cause episodes
of pain and can damage organs.
[0069] Sickle cell anemia is an autosomal recessive genetic
disorder. For the disease to be expressed, a person must inherit
either two copies of HbS variant or one copy of HbS and one copy of
another variant. Carriers, who have one copy of the normal HBB gene
(HbA) and one copy of HbS, are described as having sickle cell
trait and do not express disease symptoms.
[0070] Thus, one embodiment of the present invention provides a
method of treating subjects with sickle cell anemia. siRNA targeted
to the HBB gene is administered to the patient. The siRNA is
designed to knock down and preferably knock out the expression of
the Hbs variant of hemoglobin. A polynucleotide encoding a normal
hemoglobin is provided to the subject so the subject expresses a
normal hemoglobin. The siRNA is also designed so that it will not
interfere with expression of the exogenous polynucleotides encoding
the normal hemoglobin. Thus, the subject no longer makes the
variant hemoglobin (or makes substantially less) and instead makes
normal healthy hemoglobin, resulting in more normal red blood
cells, which function normally.
[0071] The present invention is also useful in situations where a
post translational modification occurs to the protein, which causes
or leads to a disease state. siRNA is used to knock down expression
of the endogenous protein so none or less is available for the post
translational modification. Then, a polynucleotide encoding a
protein is provided to the patient for exogenous expression. The
protein is modified so that it is unable to be post translationally
modified. This protein is then available to the body for its
appropriate use, but will not lead to the disease state because it
is not able to be post translationally modified. One skilled in the
art would understand different post translational modifications.
For example, after translation, the posttranslational modification
of amino acids extends the range of functions of the protein by
attaching to it other biochemical functional groups such as
acetate, phosphate, various lipids and carbohydrates, by changing
the chemical nature of an amino acid (e.g. citrullination) or by
making structural changes, like the formation of disulfide bridges.
Also, enzymes may remove amino acids from the amino end of the
protein, or cut the peptide chain in the middle. For instance, the
peptide hormone insulin is cut twice after disulfide bonds are
formed, and a propeptide is removed from the middle of the chain;
the resulting protein consists of two polypeptide chains connected
by disulfide bonds. Also, most nascent polypeptides start with the
amino acid methionine because the "start" codon on mRNA also codes
for this amino acid. This amino acid is usually taken off during
post-translational modification. Other modifications, like
phosphorylation, are part of common mechanisms for controlling the
behavior of a protein, for instance activating or inactivating an
enzyme. Another post translational modification includes the
hypusination of eukarotic initiation factor 5A (eIF5A) by
deoxyhypusine synthase (DHS).
[0072] Thus, the invention provides a method of altering expression
of a gene in a subject, wherein a polynucleotide encoding a protein
is provided to a patient and is expressed in the patient. The
protein may be a normal/wild type protein or a mutated protein.
Expression of the corresponding endogenous gene is suppressed with
the siRNA that is administered to the subject.
[0073] The method further comprises providing a construct
comprising a polynucleotide encoding the target protein wherein the
polynucleotide is expressed in the subject to produce the target
protein. In certain embodiments where the endogenous gene expresses
a faulty protein, the polynucleotide is designed to encode either a
normal/healthy protein. The siRNA is administered to suppress
expression of the faulty endogenous protein. In certain embodiments
where the endogenous gene expresses a normal healthy protein, the
polynucleotide is designed to encode a mutant protein that can not
be postranslationally modified as would occur with a normal/healthy
or non mutant protein. The siRNA is administered to suppress
expression of the endogenous protein so there is less of this
protein to be available for posttranslational modification.
[0074] In certain embodiments, the siRNA is chosen or designed to
target regions of the gene so as to not effect expression of the
exogenous polynucleotide. For example, the siRNA may target the 3'
UTR or 3' end.
[0075] The siRNA may be delivered to the patient as either naked
siRNA or naked siRNA stabilized for serum. The siRNA may by either
injected systemically, i.e. IP or IV. Alternatively, the siRNA may
be injected or delivered locally to the desired area of the body.
In certain embodiments, the siRNA may be administered in a delivery
vehicle such as but not limited to dendrimers, liposomes, or
polymers.
[0076] The polynucleotides encoding the desired protein may be
administered through any delivery means that provide or allow
expression of the nucleotide. The term polynucleotide and
nucleotide are used herein interchangeably. Delivery may be through
any viral or non-viral mechanism, such as but not limited to
plasmids, expression vectors, viral constructs, adenovirus
constructs, dendrimers, liposomes, or polymers.
[0077] In certain embodiments an expression plasmid having reduced
CpG dinucleotides is used to express the polynucleotides. Any
promoter capable of promoting expression of the polynucleotide may
be used, which may be chosen based on the application desired for
the therapy. For example, for killing multiple myeloma, a promoter
specific for B cells may be desirable, such as human B29
promoter/enhancer. In other embodiments, the promoter may be
another tissue specific promoter, or may be a system promoter.
[0078] The polynucleotides encoding the target protein may be
delivered through IV or subcutaneous injection or any other
biologically suitable delivery mechanism.
[0079] Alternatively, the polynucleotides may be delivered in
liposomes or any other suitable "carrier" or "vehicle" that
provides for delivery of the DNA (or plasmid or expression vector)
to the target tumor or cancer cells. See for example, Luo, Dan, et
al., Nature Biotechnology, Vol. 18, January 2000, pp. 33-37 for a
review of synthetic DNA delivery systems. Thus, it may be
preferable to deliver the nucleotides/plasmid/expression vector via
a vehicle of nanometer size such as liposomes, dendrimers or a
similar non-toxic nano-particle. The vehicle preferably protects
the nucleotides/plasmid/expression vector from premature clearance
or from causing an immune response while delivering an effective
amount of the nucleotides/plasmid/expression vector to the subject,
tumor or cancer cells. Exemplary vehicles may range from a simple
nano-particle associated with the nucleotides/plasmid/expression
vector to a more complex pegylated vehicle such as a pegylated
liposome having a ligand attached to its surface to target a
specific cell receptor.
[0080] Liposomes and pegylated liposomes are known in the art. In
conventional liposomes, the molecules to be delivered (i.e. small
drugs, proteins, nucleotides or plasmids) are contained within the
central cavity of the liposome. One skilled in the art would
appreciate that there are also "stealth," targeted, and cationic
liposomes useful for molecule delivery. See for example,
Hortobagyi, Gabriel N., et al., J. Clinical Oncology, Vol. 19,
Issue 14 (July) 2001:3422-3433 and Yu, Wei, et al., Nucleic Acids
Research. 2004, 32(5);e48. Liposomes can be injected intravenously
and can be modified to render their surface more hydrophilic (by
adding polyethylene glycol ("pegylated") to the bilayer, which
increases their circulation time in the bloodstream. These are
known as "stealth" liposomes and are especially useful as carriers
for hydrophilic (water soluble) anticancer drugs such as
doxorubicin and mitoxantrone. To further the specific binding
properties of a drug carrying liposome to a target cell, such as a
tumor cell, specific molecules such as antibodies, proteins,
peptides, etc. may be attached on the liposome surface. For
example, antibodies to receptors present on cancer cells maybe used
to target the liposome to the cancer cell. In the case of targeting
multiple myeloma, folate, II-6 or transferrin for example, may be
used to target the liposomes to multiple myeloma cells.
[0081] Dendrimers are also known in the art and provide a
preferable delivery vehicle. See for example Marjoros, Istvan, J.,
et al, "PAMAM Dendrimer-Based Multifunctional Conjugate for Cancer
Therapy: Synthesis, Characterization, and Functionality,"
Biomacromolecules, Vol. 7, No. 2, 2006; 572-579, and Majoros,
Istvan J., et al., J. Med. Chem, 2005. 48, 5892-5899 for a
discussion of dendrimers.
[0082] In a preferred embodiment, the delivery vehicle comprises a
polyethylenimine nanoparticle. An exemplary polyethylenimine
nanoparticle is the in vivo-jetPEI.TM., currently produced by
Polyplus Transfection, Inc. In vivo-jetPEI.TM. is cationic polymer
transfection agent useful as a DNA and siRNA delivery agent. In
vivo-jetPEI.TM. from Polyplus Transfection is a linear
polyethylenimine reagent that provides reliable nucleic acid
delivery in animals. It is used for gene therapy (Ohana et al.,
2004. Gene Ther Mol Bio 8:181-192; Vernejoul et al., 2002. Cancer
Research 62:6124-31), RNA interference, (Urbain-Klein et al., 2004.
Gene therapy 23:1-6; Grezelinski et al., 2006. Human Gene Therapy
17:751-66), and genetic vaccination (Garzon et al., 2005. Vaccine
23:1384-92). In vivo JET-PEI is currently in use in human clinical
trials as a delivery vector for cancer gene therapy (Lemkine et
al., 2002. Mol. Cell. Neurosci. 19:165-174).
[0083] In vivo-jetPEI.TM. condenses nucleic acids into roughly 50
nm nanoparticles, which are stable for several hours. As a result
of this unique protection mechanism, aggregation of blood cells
following injection is reduced compared to other reagents thereby
preventing restricted diffusion within a tissue, erythrocyte
aggregation and microembolia. These nanoparticles are sufficiently
small to diffuse into the tissues and enter the cells by
endocytosis. In vivo-jetPEI.TM. favors nucleic acids release from
the endosome and transfer across of the nuclear membrane.
[0084] In a preferred embodiment, both the siRNA and a
vector/plasmid comprising the polynucleotide are administered to
the subject via an in vivo-jetPEI.TM. complex. The siRNA and the
vector/plasmid comprising the polynucleotide maybe complexed
together via a polymer complex such as polyethylenimine or the in
vivo jetPEI.TM. complex or may separately complexed to a polymer.
For instance, where the siRNA and the vector/plasmid comprising the
polynucleotide are to be administered separately to the subject
(separately in the meaning of time and/or delivery site) it is
preferable to have the siRNA and the polynucleotide complexed to a
different carrier. Where the administration will be at the same
time and at the same site, it may be preferable to complex the
siRNA and the polynucleotide together.
[0085] In another embodiment, instead of a plasmid or vector being
administered to deliver a polynucleotide that will be expressed in
the subject, the protein per se is delivered to the subject. The
protein may be either isolated or may be synthetic.
[0086] One embodiment of the present invention provides a method of
treating cancer in a subject, including mammals and humans.
Treating cancer includes, but is not limited to inducing apoptosis
in cancer cells, killing cancer cells, reducing the number of
cancer cells and reducing tumor volume/weight. The method comprises
administering a composition comprising eIF5A1 siRNA and a
polynucleotide encoding a mutant eIF5A1. The composition and eIF5A1
siRNA and a polynucleotide encoding a mtuant eIF5A1 are discussed
herein below.
[0087] All cells produce eukaryotic initiation factor 5A ("eIF-5A")
(or also referred to herein as "factor 5A"). Mammalian cells
produce two isoforms of eIF-5A1 (eIF-5A1 and eIF-5A2). eIF-5A1 has
been referred to as apoptosis-specific eIF-5A, as it is upregulated
in cells undergoing apoptosis. Human eIF-5A1 has the accession
number NM 001970 and is shown in FIG. 1. It is believed that
eIF-5A1 is responsible for shuttling out of the nucleus subsets of
mRNAs encoding proteins necessary for apoptosis. eIF-5A2 has been
referred to as proliferation eIF-5A as it is believed to be
responsible for shuttling out of the nucleus subsets of mRNAs
encoding proteins necessary for cellular proliferation. See Liu
& Tartakoff (1997) Supplement to Molecular Biology of the Cell,
8, 426a. Abstract No. 2476, 37th American Society for Cell Biology
Annual Meeting, and Rosorius et al. (1999) J. Cell Science, 112,
2369-2380.
[0088] Both factor 5As are post translationally modified by
deoxyhypusine synthase ("DHS"). DHS hypusinates the eIF-5As.
Hypusine, a unique amino acid, is found in all examined eukaryotes
and archaebacteria, but not in eubacteria, and eIF-5A is the only
known hypusine-containing protein. Park (1988) J. Biol. Chem., 263,
7447-7449; Schumann & Klink (1989) System. Appl. Microbiol.,
11, 103-107; Bartig et al. (1990) System. Appl. Microbiol., 13,
112-116; Gordon et al. (1987a) J. Biol. Chem., 262, 16585-16589.
Hypusinated eIF-5A is formed in two post-translational steps: the
first step is the formation of a deoxyhypusine residue by the
transfer of the 4-aminobutyl moiety of spermidine to the
.alpha.-amino group of a specific lysine of the precursor eIF-5A
catalyzed by deoxyhypusine synthase. The second step involves the
hydroxylation of this 4-aminobutyl moiety by deoxyhypusine
hydroxylase to form hypusine.
[0089] The amino acid sequence of eIF-5A is well conserved between
species, and there is strict conservation of the amino acid
sequence surrounding the hypusine residue in eIF-5A, which suggests
that this modification may be important for survival. Park et al.
(1993) Biofactors, 4, 95-104. This assumption is further supported
by the observation that inactivation of both isoforms of eIF-5A
found to date in yeast, or inactivation of the DHS gene, which
catalyzes the first step in their activation, blocks cell division.
Schnier et al. (1991) Mol. Cell. Biol., 11, 3105-3114; Sasaki et
al. (1996) FEBS Lett., 384, 151-154; Park et al. (1998) J. Biol.
Chem., 273, 1677-1683. However, depletion of eIF-5A protein in
yeast resulted in only a small decrease in total protein synthesis
suggesting that eIF-5A may be required for the translation of
specific subsets of mRNA's rather than for protein global
synthesis. Kang et al. (1993), "Effect of initiation factor eIF-5A
depletion on cell proliferation and protein synthesis," in Tuite,
M. (ed.), Protein Synthesis and Targeting in Yeast, NATO Series H.
The recent finding that ligands binding eIF-5A share highly
conserved motifs also supports the importance of eIF-5A. Xu &
Chen (2001) J. Biol. Chem., 276, 2555-2561. In addition, the
hypusine residue of modified eIF-5A was found to be essential for
sequence-specific binding to RNA, and binding did not provide
protection from ribonucleases.
[0090] The present inventors have shown that when polynucleotides
encoding eIF-5A are administered to cells, there is an increase in
apoptosis those cells. They have shown that they have been able to
push cancer cells into apoptosis by administering eIF-5Al
polynucleotides that are then expressed in the cancer cells. See
co-pending application Ser. Nos. 10/200,148; 11/287,460; 11/293,391
and 11/637,835, all of which are incorporated by reference in their
entireties.
[0091] The present inventors have additionally determined that when
cells have a build up of the hypusinated form of factor 5A, the
cells enter into a survival mode and do not undergo apoptosis as
they normally would over time. Notably, in cancer cells, there is a
significant amount of hypusinated factor 5A and thus, the cells do
not enter into apoptosis (and do not die). Thus, to treat cancer by
killing the cancer cells (push the cancer cells to enter into the
apoptosis pathway), a polynucleotide encoding eIF-5A1 is
administered to the subject or to the cancer cells or tumor to
provide increased expression of eIF-5A1, which in turn causes
apoptosis in the cancer cells and ultimately cell death and tumor
shrinkage. However, if one were to only provide polynucleotides
encoding the eIF-5A1 protein to up regulate gene expression of
eIF-5Al and not also use siRNA to knock down endogenous expression
of eIF-5A1, there is a tug of war: the eIF-5A1 expression directing
the cells towards the apoptosis pathway competes with the presence
of the hypusinated factor 5A directing the cells towards the cell
survival pathway. The present invention eliminates this tug of war
and represents an improvement over only increasing expression of
eIF-5A1. The polynucleotides administered to the subject or cell
are mutated so that the resulting expressed protein can not be
hypusinated. In addition endogenous expression of factor 5A is
knocked out/down with siRNA targeted against eIF-5A so there is
none/less endogenous eIF-5A1 around to by hypusinated. Thus, since
there is no (or substantially less) hypusinated eIF-5A in the
cells, they are not pushed into survival mode.
[0092] The polynucleotide encoding a mutated eIF-5A1 is preferably
mutated so that it can not be hypusinated and thus will not be
available to drive the cell into survival mode. For example, in one
embodiment, the polynucleotide encoding eIF-5A is mutated to so
that the lysine (K) at position 50, which is normally hypusinated
by DHS, is changed to an alanine (A) (which can not be
hypusinated). This mutant is denoted as K50A.
[0093] In another embodiment, the lysine at position 67 is changed
to an arginine (R). This mutant is denoted as (K67R). In another
embodiment the lysine (K) at position 67 is changed to an alanine
(A) and is denoted as (K67A). In another embodiment, the lysine (K)
at position 50 is changed to an arginine (K50R) and another
embodiment provides a mutant where the lysine (K) at position 47 is
changed to an arginine (K47R).
[0094] In other embodiments, a double mutant is used. One double
mutant is where the lysine (K) at position 50 is changed to an
arginine (R) and the lysine (K) at position 67 is changed to a
arginine (R). This double mutant is referred to as K50R/K67R. This
double mutant is similarly unable to be hypusinated but the changes
in the amino acids do not alter the 3-D structure of eIF-5A1 as
much as the single mutation (K50A). The double mutation thus
provides a protein that is very similar in 3-D shape and folding as
the wild type and thus is more stable than the single mutant. Being
more stable, it exists longer in the body to provide longer
therapeutic benefit. Thus, the body will have the factor 5A it
needs for normal cell function but it will not be able to
hypusinated so the cells do not get locked into the cell survival
mode and escape apoptosis.
[0095] Another double mutant is where the lysine (K) at position 47
is changed to an arginine (R) and the lysine at position 50 is
changed to an arginine (R). This mutant is denoted as (K47R/K50R).
The invention provides another double mutant where the lysine (L)
at position 50 is changes to an alanine (A) and the lysine at
position 67 is changes to an alanine (A). This mutant is denoted as
(K50A/K67A).
[0096] Because the body needs factor 5A for normal cell survival
and healthy cell proliferation, it is preferable not to shut off
expression completely in the subject with the siRNA, if the siRNA
is delivered systemically. Control of eIF-5A expression can be
achieved by either using an siRNA that is not as good at shutting
off expression (i.e. shuts down or reduces expression but does not
completely shut off expression) or alternatively, or utilizing a
dosing and/or treatment regimen to balance expression levels to
allow normal growth and functioning of healthy cells but also to
push cancerous cells to apoptosis.
[0097] Alternatively, one may utilize local delivery of siRNA. If
the siRNA is delivered locally to the cancer cell or tumor, then
the expression is preferably knocked out. By knocking out
expression, there is no factor 5A around that can be hypusinated
and thus there is no hypusinated eIF-5A to lock the cells into
survival mode. Since the siRNA is delivered locally to the cancer
or tumor, there is no need to have eIF-5A available for regular
cell growth.
[0098] In certain embodiments, the endogenous gene is eIF5A1. siRNA
targeted against eIF5A1 is administered to the subject to suppress
expression of the endogenous eIF-5A1. In certain embodiments the
siRNA comprises SEQ ID NO:1 or SEQ ID NO:2 or is any siRNA targeted
against eIF5A1 that will suppress expression of endogenous eIF-5A1.
In certain embodiments, the eIF5A1 is human eIF-5A1 (shown in FIG.
1) and the subject is a human. Other siRNAs targeted against human
eIF-5A1 are known and disclosed in co-pending application Ser. Nos.
11/134,445; 11/287,460; 11/184,982; 11/293,391; 11/725,520;
11/725,470; 11/637,835. In other embodiments, the subject is a
mammal and the eIF5A1 is specific to the mammal. For example, the
subject is a dog and the eIF5A1 is canine eIF5A1. In certain
embodiments, the siRNA consists essentially of the siRNA construct
shown in FIG. 25. For example, the siRNA contains nucleic acids
targeted against the eIF5A1 but also contains overhangs such as U
or T nucleic acids or also contains tags, such as a his tag (often
referred to as HA tag which is often used in in vitro studies).
Molecules or additional nucleic acids attached at either the 5' or
3' end (or even within the consecutive string of nucleic acids
shown in FIG. 25, for example) may be included and fall within the
"consisting essentially of" as long as the siRNA construct is able
to reduce expression of the target gene. Preferably the siRNA
targets regions of the eIF5A1 gene so as to not effect expression
of the exogenous polynucleotide. For example the eIF5A1 siRNA
targets the 3' UTR or the 3' end. The siRNA shown in FIG. 25 an
exemplary eIF5A1 siRNA.
[0099] The polynucleotide encodes eIF5A1 wherein the polynucleotide
is mutated to encode an eIF5A1 variant. The mutated eIF5A1 is
designed so that the variant eIF5A1 can not be post translationally
modified (can not be hypusinated). Exemplary mutants are discussed
herein above.
[0100] In the case of cancer involving solid tumors, it may be
desirable to deliver the siRNA directly to the tumor. The siRNA
maybe administered separately with respect to time as well as the
delivery site from the polynucleotide or may administered together
at the same time and/or at the same delivery site. One skilled in
the art would understand that the timing of administration of the
siRNA may be necessarily administered when the endogenous protein
is being translated and not after it is already made.
[0101] Although the present inventors have earlier shown that
eIF5A1 is non toxic to normal tissue (see pending application Ser.
No. 11/293,391, filed Nov. 28, 2005, which is incorporated herein
by reference in its entirety), a delivery complex (as compared to
direct administration of the eIF5A
polynucleotides/plasmid/expression vector) may be preferred. A
preferred delivery system provides an effective amount of eIF5A1 to
the subject, tumor or group of cancer cells, as well as preferably
provides a targeted delivery to the tumor or group of cancer cells.
Thus, in certain embodiments, it is preferable to deliver the
eIF5A1 nucleotides/plasmid/expression vector via a vehicle of
nanometer size such as liposomes, dendrimers or a similar non-toxic
nano-particle such as a polyethylenimine polymer (such as an in
vivo JetPEI.TM. complex).
[0102] The eIF5A1 protein may also be delivered directly to the
site of the tumor. One skilled in the art would be able to
determine the dose and length of treatment regimen for delivery of
eIF5A1 protein.
[0103] The molecular basis for the induction of apoptosis by eIF5A1
is discussed below.
Death Receptor Signaling
[0104] Treatment of cancer cells with Ad-eIF5A1 (adenovirus with a
wild type eIF5A1) or Ad-eIF5A1(K50A) induces activation of caspase
8, which is initiated by death receptor-ligand binding, and caspase
3, the executioner caspase. These are likely to be indirect effects
of eIF5A1, and the fact that caspase 8 and caspase 3 are also
activated following treatment with eIF5A1(K50A), which cannot be
hypusinated, indicates that the effect is attributable to lysineso
eIF5A1. Treatment with Ad-eIF5A1 also appears to result in
up-regulation of death receptors as shown previously with
upregulation of TNFR1.
Mitochondrial Pathway
[0105] Direct or indirect involvement of lysine.sub.50 eIF5A1 in
the mitochondrial pathway for apoptosis is supported by a number of
observations including the finding that caspase 9 is activated by
treatment of cancer cells with either eIF5A1 or eIF5A1(K50A). As
well, p53, which plays a role in activation of the mitochondrial
apoptotic pathway, appears to be regulated by eIF5A1. For example,
treatment of cancer cells with Actinomycin D up-regulates p53, and
this up-regulation of p53 is inhibited by eIF5A1 siRNA. Consistent
with this, treatment of cancer cells with Ad-eIF5A1 up-regulates
p53 mRNA. Treatment of cancer cells with eIF5AI also induces
migration of Bax from the cytosol to mitochondria, ensuing loss of
mitochondrial membrane potential and release of cytochrome C from
the intramitochondrial space into the cytosol. In addition, this
treatment results in up-regulation of cleaved Bcl2, Bim and spliced
Bim, which are all pro-apoptotic.
MAPK Signaling
[0106] In addition, the present inventors have obtained evidence
for the involvement of eIF5A1 in MAPK signaling related to
apoptosis. For example, treatment of cancer cells with Ad-eIF5A1
up-regulated P-JNK, which in turn inhibits anti-apoptotic Bcl2. In
addition Ad-eIF5A1 and Ad-eIF5A1(K50A) both induce the formation of
P-p38, which can in turn initiate apoptosis by impacting a variety
of pro-apoptotic agents including TNFR1 & TNF; FAS & FASL;
caspase 8; Bid; Cytochrome C and Capase 3.
NF-.kappa.B Signaling
[0107] There is evidence that NF-.kappa.B signaling supports
myeloma growth. For example, myeloma cell adhesion to bone marrow
stromal cells induces NF-.kappa.B-dependent transcriptional
up-regulation of IL-6, which is both a growth and anti-apoptotic
factor in multiple myeoloma [Chauhan et al. (1996) Blood 87, 1104.]
In addition, TNF-.alpha. secreted by myeloma cells activates
NF-.kappa.B in bone marrow stromal cells, thereby up-regulating
IL-6 transcription and secretion. TNF-.alpha. also activates
NF-.kappa.B in myeloma cells resulting in up-regulation of the
intracellular adhesion molecule-1 (ICAM-1; CD54) and the vascular
cell adhesion molecule-1 (VCAM-1; CD106) on both myeloma cells and
bone marrow stromal cells [Hideshima et al. (2001) Oncogene 20,
4519]. This in turn enhances the association of myeloma cells with
bone marrow stromal cells [Hideshima et al. (2001) Oncogene 20,
4519]. Conversely, these effects are inhibited by blocking
TNF.alpha.-induced NF-.kappa.B activation [Hideshima et al. (2001)
Oncogene 20,4519]. Indeed, it seems likely that NF-.kappa.B
mediates protection against TNF.alpha.-induced apoptosis in myeloma
cells [Hideshima et al. (2002) JBC 277, 16639]. These and other
observations have prompted the view that NF-kB signaling may be an
attractive target for multiple myeloma therapies.
[0108] The inventors have shown that eIF5A1 siRNA inhibits both the
activation of NF-.kappa.B and the formation of ICAM-1 in human
myeloma cells. These observations indicate that eIF5A1 plays a role
in NF-.kappa.B activation, and inasmuch as the ensuing effects of
NF-.kappa.B activation are pro-survival in nature, we predict that
this activation is mediated, directly or indirectly, by hypusinated
eIF5A1.
IL-1
[0109] Over-production of the pro-inflammatory cytokine, IL-1, by
myeloma cells is a characteristic feature of multiple myeloma that
leads to deterioration of bone tissue. eIF5A1 siRNA has been shown
to dramatically reduce the overproduction of IL-1 induced by an LPS
challenge in mice.
[0110] One embodiment of the present invention provides a method of
treating multiple myeloma. Multiple myeloma ("MM") is a progressive
and fatal disease characterized by the expansion of malignant
plasma cells in the bone marrow and by the presence of osteolytic
lesions. Multiple myeloma is an incurable but treatable cancer of
the plasma cell. Plasma cells are an important part of the immune
system, producing immunoglobulins (antibodies) that help fight
infection and disease. Multiple myeloma is characterized by
excessive numbers of abnormal plasma cells in the bone marrow and
overproduction of intact monoclonal immunoglobulins (IgG, IgA, IgD,
or IgE; "M-proteins") or Bence-Jones protein (free monoclonal light
chains). Hypocalcaemia, anemia, renal damage, increased
susceptibility to bacterial infection, and impaired production of
normal immunoglobulin are common clinical manifestations of
multiple myeloma. Multiple myeloma is often also characterized by
diffuse osteoporosis, usually in the pelvis, spine, ribs, and
skull.
[0111] The present invention seems to be well suited to treat
multiple myeloma because of the stimulation feedback loop found in
multiple myeloma. For instance, multiple myeloma produces Il-1 in
low concentrations in bone marrow. The Il-1 in turn stimulates
stromal cells to produce IL-6, which then goes onto stimulate
growth of the multiple myeloma. The inventors have previously shown
(see pending application Ser. Nos. 11/725,539 and 11/184,982) that
siRNA directed against eIF-5A1 was able to inhibit expression of
proinflammatory cytokines, such as Il-1; TNF-.alpha., and Il-8).
Thus, the siRNA would not only knock down expression of eIF-5A so
less is available for hypusination, it would also cut off or
decrease the Il-1/Il-6 feedback loop.
[0112] An siRNA targeting human eIF5A was used to suppress levels
of endogenous hypusinated eIF5A in tumours, while an RNAi-resistant
plasmid expressing a mutant of eIF5A (eIF5A.sup.K50R), that is
incapable of being hypusinated, was used to raise the levels of
unmodified eIF5A in vivo. Intra-tumoural injection of PEI
nanocomplexes containing eIF5A siRNA inhibited MM tumour growth by
more than 80% (***p=0.0003) versus complexes containing a control
siRNA, indicating that suppressing levels of hypusinated eIF5A has
an anti-tumoural effect. PEI complexes containing an eIF5A.sup.K50R
expression plasmid had a similar effect and inhibited tumour growth
by more than 70% (**=p 0.001) versus complexes containing a control
plasmid. Thus, MM tumour growth can be inhibited either by
suppression of the growth-promoting hypusinated eIF5A or by
increasing levels of the pro-apoptotic unhypusinated form of eIF5A.
Intra-tumoural delivery of complexes containing both eIF5A siRNA
and RNAi-resistant eIF5A.sup.K50R plasmid had a synergistic effect
on tumour growth and resulted in significant tumour shrinkage,
inhibiting tumour growth by 94% (***p=0.0002). Intra-venous
delivery of eIF5A siRNA/eIF5A.sup.K50R PEI complexes also
efficiently reduced tumour growth by 95% (**p=0.002) indicating
systemic delivery of the therapeutic is feasible.
[0113] Both local and systemic delivery of eIF5A
siRNA/eIF5A.sup.K50R pDNA PEI complexes resulted in a significant
anti-tumoural response in multiple myeloma.
[0114] The present invention further provides a composition useful
in the treatment of cancer, including multiple myeloma. In a
preferred embodiment, the composition is a complex of a plasmid DNA
encoding point-mutated eIF5A1 that cannot be hypusinated and eIF5A1
siRNA that selectively suppresses endogenous human eIF5A1 but has
no effect on the point-mutated eIF5A1 encoded by the plasmid. eIF5A
siRNAs and polynucleotides encoding mutant eIF5A are discussed
above. The plasmid DNA and the siRNA are both preferably complexed
to PEI (polyethylenimine) nanoparticles. They may be complexed
separately and administered separately or together or they may be
complexed together. The DNA and the RNA bind to positively charged
amino groups on the PEI and are released when the nanoparticles are
taken up into cells. It has been demonstrated that PEI-nucleic acid
complexes are effectively taken up into both dividing and
non-dividing cells.
[0115] The plasmid DNA preferably encodes eIF5AI(K50R) which, like
eIF5A1(K50A), cannot be hypusinated and, accordingly, is strongly
apoptogenic. The expression of eIF5AI(K50R) is preferably regulated
by a B-cell-specific promoter.
[0116] The eIF5A1 siRNA is preferably specific to the 3'-end of
endogenous human eIF5A1 and has no effect on expression of the
trans eIF5A1(K50R). An exemplary preferred eIF5A1 siRNA comprises,
consists essentially of or consists of the siRNA shown in FIG. 25.
The rationale for including the eIF5A1 siRNA is: (1) to deplete
endogenous eIF5A1, which is almost all hypusinated and hence in the
pro-survival form; (2) to inhibit activation of NF-.kappa.B, and
thereby reduce the production of IL-6 and the formation of
intracellular adhesion molecules; and (3) to inhibit the formation
of IL-1. That eIF5A1 siRNA acts synergistically with eIF5A1(K50R)
to induce apoptosis in myeloma cells. Inasmuch as (2) and (3) above
are pro-survival events, they are likely mediated by hypusinated
eIF5A1, and hence not affected by eIF5A(K50R) which cannot by
hypusinated. This approach results in a larger pool of
unhypusinated eIF5A leading to apoptosis of cancer cells, including
multiple myeloma cells, with little effect on healthy cells.
[0117] A preferred composition is referred to herein as SNS01.
SNS01 is a complex containing both, an RNAi-resistant plasmid DNA
encoding eIF5A.sup.K50R driven by a promoter that restricts
expression to cells of B-cell origin (including myeloma cells) for
enhanced safety, and an siRNA targeting human eIF5A with dTdT 3'
overhangs for enhanced nuclease resistance and which the siRNA and
the plasmid are complexed to in vivo JetPEI.TM..
EXAMPLES
Example 1
Transfection of HeLaS3 Cells with Wild Type and Variants of
eIF-5A1
[0118] HeLa S3 cells were transfected using Lipofectamine 2000 with
plasmids expressing HA-tagged eIF5A1 variants including wild-type
eIF5A1 (WT), eIF5A1K50R (K50R), eIF5A1K67R (K67R), eIF5A1K67A
(K67A), eIF5A1K47R/K50R (K4750R), eIF5A1K50R/K67R (K5067R), or
eIF5A1K50A/K67A (K5067A). A plasmid expressing LacZ was used as a
control. At 24 and 48 hours (A) or 28 and 52 hours (B) after
transfection, the cell lysate was harvested and fractionated by
SDS-PAGE. Expression levels of transfected eIF5A1 was detected
using an antibody against HA. Result: Mutation of eIF5A1 at a
lysine in the putative ubiquination site (K67R) increased the 5
accumulation of the eIF5A1 transgene above wild-type (A). Mutation
of eIF5A1 at the lysine required for hypusination (K50R) also
increased accumulation of eIF5A1 transgene above wild-type eIF5A1
(B). A double mutant form of eIF5A1 (K50A/K67A) was expressed
particularly well when compared to the unmutated wild-type eIF5A1
transgene (A+B). See FIGS. 2A and 2B.
Example 2
Transfection of KAS Cells with Wild Type and Variants of
eIF-5A1
[0119] KAS cells were transfected using PAMAM dendrimer (FMD44)
with plasmids expressing HA-tagged eIF5A1 variants including
wild-type eIF5A1 (5A1), eIF5A1K67A (K67A), eIF5A1K50A/K67A (K50A
K67A), eIF5A1K50R (K50R), eIF5A1K47R (K47R), eIF5A1K67R (K67R),
eIF5A1K47R/K5OR (K47R K5OR), or eIF5A1K50R/K67R (K50R K67R). A
plasmid expressing LacZ was used as a control. 48 hours (after
transfection, the cell lysate was harvested and fractionated by
SDS-PAGE. Expression levels of transfected eIF5A1 was detected
using an antibody against HA. Equal loading was verified using an
antibody against actin. Result: Mutation of eIF5A1 at a lysine in
the putative ubiquination site (K67A or K67R) increased the
accumulation of the eIF5A1 transgene above wild-type. Mutation of
eIF5A1 at the lysine required for hypusination (K5OR) or at an
acetylation site (K47R) also increased accumulation of eIF5A1
transgene above wild-type eIF5A. A double mutant form of eIF5A1
(K50A/K67A) was also expressed at higher levels when compared to
the unmutated wild-type eIF5A1 transgene. See FIG. 3.
Example 3
Transfection of KAS Cells Using PAMAM Dendrimer
[0120] KAS cells were transfected using PAMAM dendrimer (FMD45-2)
with plasmids expressing HA-tagged eIF5A1 variants including
eIF5A1K5OR (K5OR), eIF5A1K50A/K67A (K50A/K67A), or eIF5A1K50R/K67R
(K50R K67R). A plasmid expressing LacZ was used as a control.
Seventy-two hours after transfection, the cells were stained with
Annexin/PI and analyzed by FACS. Cells that stained positively for
Annexin V and negatively for PI (propidium iodide) were considered
to be in the early stages of apoptosis (Ann+/PI-) and cells that
stained positively for both Annexin V and PI were considered to be
in the late stages of apoptosis (Ann+/PI+). Result: Mutation of
eIF5A1 at a lysine in the hypusination site (K50R) or in the
putative ubiquination site (K67R), as well as the double mutant
(K50A/K67A) resulted in apoptosis of KAS cells significantly above
the levels of the LacZ control. See FIG. 4.
Example 4
Transfection of KAS Cells with Plasmids Expressing eIF-5A1 and
eIF-5A1 Variants
[0121] KAS cells were transfected using Lipofectamine 2000 with
plasmids expressing HA-tagged eIF5A1 variants including eIF5A1K50A
(K50A), eIF5A1K50R (K50R), eIF5A1K67R (K67R), eIF5AI K50A/K67A
(K50A/K67A), or eIF5A1K50R/K67R (K50R K67R). A plasmid expressing
LacZ was used as a control. Seventy-two hours after transfection,
the cells were stained with Annexin/PI and analyzed by FACS. Cells
that stained positively for Annexin V and negatively for PI
(propidium iodide) were considered to be in the early stages of
apoptosis (Ann+/PI-) and cells that stained positively for both
Annexin V and PI were considered to be in the late stages of
apoptosis (Ann+/PI+). Result: Mutation of eIF5A1 at a lysine in the
hypusination site (K50R) or In the putative ubiquination site
(K67R), as well as the double mutant (K50A/K67A) resulted in
apoptosis of KAS cells significantly above the levels of the LacZ
control. See FIG. 5.
Example 5
The Use of Mutated eIF-5A1 to Treat KAS Cells Results in
Apoptosis
[0122] KAS cells were transfected using Lipofectamine 2000 with
plasmids expressing HA-tagged eIF5A1 variants eIF5A1K50R (K50R) or
eIF5A1K50A/K67A (K50A/K67A. A plasmid expressing LacZ was used as a
control. Seventy-two hours after transfection, the cells were
stained with Annexin/PI and analyzed by FACS. Cells that stained
positively for Annexin V and negatively for PI (propidium iodide)
were considered to be in the early stages of apoptosis (Ann+/PI-)
and cells that stained positively for both Annexin V and PI were
considered to be in the late stages of apoptosis (Ann+/PI+).
Result: Mutation of eIF5A1 at a lysine in the hypusination site
(K50R) or mutation of eIF5A1 at both the hypusination site and in
the putative ubiquination site (K50A/K67A) resulted in apoptosis of
KAS cells significantly above the levels of the LacZ control. See
FIG. 6.
Example 6A
siRNA/Adenovirus-Mediated Killing of Multiple Myeloma Cells
[0123] KAS (human multiple myeloma) cells were maintained in S10
media [RPMI 1640 with 4 ng/ml IL-6, 10% fetal bovine serum (FBS),
and penicillin/streptomycin (P/S)]. KAS cells were transfected with
58.7 pmoles of siRNA using Lipofectamine 2000 (Invitrogen). Mock
transfected cells were treated with Lipofectamine 2000 in the
absence of siRNA. Transfection was conducted in the antibiotic-free
S10 media.
[0124] a) siRNAs Targeting Human eIF5A1:
TABLE-US-00001 eIF5A1 siRNA target #1 (the siRNA targets this
region of human eIF5A1: (SEQ ID NO: __)
5'-AAGCTGGACTCCTCCTACACA-3'. The siRNA sequence is shown in FIG. 25
and is often referred to herein as h5A1. eIF5A1 siRNA target #2
eIF5A1 (this siRNA targets this region of human eIF5A1: (SEQ ID NO:
__) 5'-AAAGGAATGACTTCCAGCTGA-3'. (The siRNA sequence is often
referred to herein ash5A1-ALT) b) control siRNA: The control siRNA
had the following sequence: sense strand,
5'-ACACAUCCUCCUCAGGUCGdTdT-3'; and antisense strand,
3'-dTdTUGUGUAGGAGGAGUCCAGC-5'''.
[0125] Other controls that have been used include non-targeting
validated siRNAs from Dharmacon since they have been micro-array
tested to limit unwanted off-targeting effects. For example, for in
vitro work studyign NFkB, the control used was Dharmacon's
non-targeting siRNA's (sequence D-001700-01) and for in vivo work,
the control used was Dharmacon's (sequence D-001810-01).
[0126] Four hours after transfection, the cells were pelleted and
resuspended in 1 ml of S10 media. Seventy-two hours after the
initial siRNA transfection, the transfected KAS cells were counted
and seeded at 300,000 cells/well in a 24-well plate and transfected
with the same siRNA a second time.
[0127] Four hours after transfection, the cells were pelleted and
resuspended in 1 ml of S10 media (without IL-6) containing 3000 ifu
of either Ad-LacZ (Adenovirus expressing B-galactosidase) or
Ad-5A1M (Adenovirus expressing human eIF5A1.sup.K50A).
[0128] Seventy-two hours later the cells were harvested and
analyzed for apoptosis by staining with Annexin V-FITC and PI (BD
Bioscience) followed by FACS analysis. [0129] a) early apoptosis
was defined as cells that were positively stained with Annexin-FITC
and negative for PI-staining (Ann+/PI-) [0130] b) total apoptosis
was defined as the total of cells either in early apoptosis
(Ann+/PI-) or late apoptosis/necrosis (Ann+/PI+)
[0131] The 5A1 siRNA targeting #1 targets the 3'UTR of human eIF5A1
and therefore will not affect expression of eIF5A1 from adenovirus.
5A1 siRNA targeting #2 targets within the open reading frame of
human eIF5A1 and so it could potentially interfere with expression
of eIF5A1 from the adenovirus.
[0132] Results: Cells treated with siRNA and infected with
adenovirus expressing the eIF-5A1 K50A variant undergo apoptosis in
greater numbers than non-treated cells and cells treated only with
siRNA. See FIG. 7.
Example 6B
Pre-Treatment with eIF5A1 siRNA Against eIF5A1 Target #1 (Shown in
FIG. 25), Reduced Expression of Endogenous eIF5A1 but Allows
Accumulation of RNAi-Resistant eIF5A1.sup.k50A Expressed by
Adenovirus
[0133] KAS cells were transfected using Lipofectamine 2000 with
either a control siRNA (C) or one of two siRNAs targeting eIF5A1
(#1 and #2). The eIF5A1 siRNA #1 targets the 3'UTR of eIF5A1 and
therefore does not interfere with expression of eIF5A1 from
adenovirus since it contains only the open reading frame of eIF5A1.
The sequence of the siRNA is shown in FIG. 25. The eIF5A1 #2 siRNA
targets the open reading frame of eIF5A1 and will therefore affect
expression of both endogenous and exogenously-expressed eIF5A1.
Seventy-two hours after the initial transfection hours the cells
were transfected with the same siRNA a second time. Four hours
later the transfection complexes were removed from the cells and
replaced with growth media (-) IL6 containing either Ad-LacZ (L) or
Ad-eIF5A.sup.K50A (5M). Seventy-two hours later the cell lysate was
harvested and analyzed by Western blot using antibodies against
eIF5A and actin. See FIG. 7B. Accumulation of virally expressed
eIF5A1 can be observed (lane 1 vs lane 2) and reduction of eIF5A
expression by eIF5A1 siRNAs targeting #1 and #2 can be clearly seen
(lanes 5 and 7 vs lane 3). As expected, the eIF5A1 siRNA #1 does
not affect accumulation of the virally expressed eIF5A1.sup.K50A
(lane 6 vs lane 4) while the eIF5A1 siRNA #2 only moderately
affects expression of the virally-expressed transgene (lane 8 vs
lane 4).
Example 6C
Pre-Treatment with eIF5A1 siRNA Against Target #1 Prior to
Adenovirus Infection Reduces Expression of Phosphorylated
NF-.kappa.B in Human Multiple Myeloma Cells
[0134] KAS cells were transfected using Lipofectamine 2000 with
either a control siRNA (hC) or an siRNA targeting eIF5A1 (#1). The
eIF5A1 siRNA #1 targets the 3'UTR of eIF5A1 and will therefore not
interfere with expression of eIF5A1 from adenovirus since it
contains only the open reading frame of eIF5A1. Seventy-two hours
after the initial transfection hours the cells were transfected
with the same siRNA a second time. Four hours later the
transfection complexes were removed from the cells and replaced
with growth media (+) IL6 containing either Ad-LacZ (L) or
Ad-eIF5A1.sup.K50A (5M). Twenty-four hours later the cell lysate
was harvested and analyzed by Western blot using antibodies against
phospho-NF-kB p65 (Ser 536) and eIF5A. As expected, the eIF5A1
siRNA #1 does not affect accumulation of the virally expressed
eIF5A1.sup.K50A. Phosphorylation of NF-kB p65 at serine 536
regulates activation, nuclear localization, protein-protein
interactions, and transcriptional activity. See FIG. 7C.
Example 6D
Pre-Treatment with eIF5A1 siRNA #1 Prior to Adenovirus Infection
Reduces Expression of Phosphorylated NF-kB and ICAM-1 in Human
Multiple Myeloma Cells
[0135] KAS cells were transfected using Lipofectamine 2000 with
either a control siRNA (C) or one of two siRNAs targeting eIF5A1
(#1 and #2). Seventy-two hours after the initial transfection hours
the cells were transfected with the same siRNA a second time. Four
hours later the transfection complexes were removed from the cells
and replaced with growth media (+) IL6. Twenty-four hours after the
second transfection, the cells were stimulated with 40 ng/ml
TNF-.alpha. and cell lysate was harvested at 0, 4, or 24 hours and
analyzed by Western blot using antibodies against phospho-NF-kB p65
(Ser 536), ICAM-1 and actin. A reduction in TNF-.alpha. induced
NF-kB p65 phosphorylation (ser 536) and ICAM-1 expression was
observed following transfection with both eIF5A1-specific siRNAs.
Phosphorylation of NF-kB p65 at serine 536 regulates activation,
nuclear localization, protein-protein interactions, and
transcriptional activity. ICAM-1 is an inter-cellular adhesion
surface glycoprotein that is believed to be involved in the
pathogenesis of multiple myeloma. See FIG. 7D.
Example 6E
Pretreatment of KAS Cells with siRNA Increases Apoptosis by
eIF5A1.sup.k50R Gene Delivery in the Presence of IL-6
[0136] KAS cells were transfected with either control siRNA (hcon)
or human eIF5A1 siRNA (h5A1) using Lipofectamine 2000. Seventy-two
hours later the cells were re-transfected with siRNA. PEI complexes
of empty vector (mcs) or eIF5A1.sup.k50R (K50R) plasmids were added
to the cells four hours later following removal of siRNA
transfection medium. The growth medium used throughout the study
contained IL-6. Apoptosis was measured seventy-two hours later by
staining the cells with Annexin/PI and FACS analysis. See FIG.
7F.
Example 7
Co-Administration of eIF-5A1 Plasmid and eIF-5A1 siRNA Delays
Growth of Multiple Myeloma Subcutaneous Tumors (FIGS. 8-10)
[0137] SCID mice were injected subcutaneously with KAS cells.
Treatment was initiated when palpable tumours were observed. Six
3-5 week old SCID/CB17 mice were injected with 10 million KAS-6/1
myeloma cells in 200 .mu.L PBS in their right flank and treatment
was initiated when the tumours reached a minimum size of 4
mm.sup.3.
[0138] Control mice were injected intra-tumourally 2 times per week
with PEI complexes containing pCpG-mcs (empty vector) and control
siRNA (control group was made up of 3 mice: C-1, C-2, and C-3).
Treated mice were injected intra-tumourally 2 times per week with
PEI complexes containing the RNAi-resistant plasmid pCpG-eIF5A1k50R
and eIF5A1 siRNA (treated group was made up of 3 mice: 5A-1, 5A-2,
and 5A-3). Injections were given at multiple sites within the tumor
to prevent reflux and a slow rate of injection was used to increase
uptake. The data in FIG. 8 shows the tumor volume for all the mice
in the group. The data shown in FIG. 9 is the average tumor volume
per group +/-standard error. Asterix denote statistical
significance (*=p<0.025; n=3).
[0139] FIG. 10 shows that co-administration of eIF-5A1 plasmid and
eIF-5A1 siRNA reduces the weight of multiple myeloma subcutaneous
tumors. The data shown is the average tumor weight per group
+/-standard error. Asterix denote statistical significance
(*=p<0.05; n=3).
[0140] JET-PEI (PolyPlus) at 2.times.0.1 ml was used for the in
vivo tests. The N/P ratio was 8. The PEI/DNA/siRNA complexes were
formed in a total volume of 0.1 ml in 5% glucose. The protocol for
forming complexes was as follows. [0141] 1. Bring components to
room temperature. Keep sterile. [0142] 2. Dilute 20 .mu.g of
plasmid DNA (.about.10 .mu.l at 2 mg/ml) and 10 .mu.g siRNA (10
.mu.l at 1 mg/ml) into a total volume of 25 .mu.l. Use sterile
water to make up difference. [0143] 3. Adjust the volume of DNA
solution to 50 .mu.l 5% glucose by adding 25 .mu.l of 10% glucose.
Vortex gently and centrifuge briefly. [0144] 4. Dilute 4.8 .mu.l of
in vivo JETPEI into a total volume of 25 .mu.l of 10% glucose.
Adjust volume to 50 .mu.l with sterile water to end up with a final
concentration of 5% glucose. Vortex gently and centrifuge briefly.
[0145] 5. Immediately add 50 .mu.l of diluted PEI to the 50 .mu.l
of diluted DNA (do not reverse the order). Vortex briefly and
immediately spin down. [0146] 6. Incubate for 15 minutes prior to
injection. Complexes are stable for 6 hours.
[0147] CpG-free Cloning Vectors and pCpG Plasmids were obtained
from InvivoGen. These plasmids are completely devoid of CpG
dinucleotides, named pCpG. These plasmids yield high levels of
transgene expression both in vitro and in vivo, and in contrast to
CMV-based plasmids allow sustained expression in vivo. pCpG
plasmids contain elements that either naturally lack CpG
dinucleotides, were modified to remove all CpGs, or entirely
synthesized such as genes encoding selectable markers or reporters.
Synthesis of these new alleles was made possible by the fact that
among the sixteen dinucleotides that form the genetic code, CG is
the only dinucleotide that is non-essential and can be replaced.
Eight codons contain a CG encoding for five different amino acids.
All eight codons can be substituted by at least a choice of two
codons that code for the same amino acid to create new alleles that
code for proteins having amino acid sequences that remain identical
to the wild type and thus are as active as their wild-type
counterparts. These new alleles are available individually in a
plasmid named pMOD from which they can be easily excised.
[0148] pCpG plasmids allow long lasting expression in vivo, and
represent valuable tools to study the effects of CpGs on gene
expression in vive and in vitro, using cell lines expressing TLR9,
as well as their effects on the innate and acquired immune
systems.
[0149] The empty vector, pCpG-mcs (Invivogen) is a vector with no
expressed gene product, only a multiple cloning site, and was used
as the control vector. An HA-tagged eIF5A1.sup.k50R cDNA was
subcloned into the NcoI and NheI sites of a pCpG-LacZ vector
(Invivogen), from which the LacZ gene had been removed, to give
rise to the treatment vector pCpG-eIF5A1(K50R). The DNA was
prepared using Endo-Free Qiagen kit. Endotoxin levels measured and
are <0.03 EU/ug; DNA should be at 2 mg/ml in water.
[0150] The control siRNA used in the experiments was a micro-array
validated non-targeting control siRNA from Dharmacon (D-001810-01).
The siRNA was obtained with a modification (siSTABLE) to prevent
degradation in serum.
[0151] The eIF5A1 siRNA used in the experiments was designed
against the 3'UTR of human eIF5A1. There is no similarity between
the eIF5A1 siRNA and mouse eIF5A1 and the siRNA should therefore
only suppress human (but not mouse) eIF5A1. The siRNA also has no
similarity to eIF5A2 (either human or mouse). The siRNA was
obtained with a modification (siSTABLE) to prevent degradation in
serum. The eIF5A1 siRNA has the following target sequence:
TABLE-US-00002 5' GCU GGA CUC CUC CUA CAC A (UU) 3
[0152] The siSTABLE siRNA was dissolved at 1 mg/ml in water (stored
in aliquots at -20 C).
[0153] Tumour dimensions of length (l) and width (w) were measured
2-3 times per week using digital calipers. Tumour volume was
calculated according to the following equation:
[0154] l=length; smallest dimension
[0155] w=width; largest dimension
tumour volume (mm.sup.3)=l.sup.2*w*0.5
Statistical Analyses
[0156] Student's t-test was used for statistical analysis.
Significance was deemed to be a confidence level above 95%
(p<0.05).
Example 8
Co-Administration of eIF5A1 Plasmid and eIF5A1 siRNA Delays Growth
of Multiple Myeloma Subcutaneous Tumors and Results in Tumor
Shrinkage
[0157] In another study, again SCID mice were injected
subcutaneously with KAS cells. Treatment was initiated when
palpable tumours were observed. Control mice were injected
intra-tumourally 2 times per week with PEI complexes containing
pCpG-mcs (empty vector) and control siRNA (control group G-1, G-2
and G-3). Treated mice were injected intra-tumourally 2 times per
week with PEI complexes containing the RNAi-resistant plasmid
pCpG-eIF5A1k50R (20.g of plasmid DNA) and eIF5A1 siRNA (10 g of
siRNA) (treated group G-4, G-5 and G-6). The data shown in FIG. 11
is the average tumour volume per group +/-standard error. Asterix
denote statistical significance (*=p<0.025; n=3). Six injections
over a period of 21 days were given (red arrows).
Example 9
Administration of eIF5A1 siRNA Intra-Venously (i.v.) and
PEI/eIF5A1K50R Plasmid Complexes Intra-Tumourally (i.t.) Results in
Tumour Shrinkage of Multiple Myeloma Subcutaneous Tumours (Group
2B)
[0158] SCID mice were injected subcutaneously with KAS cells. When
palpable tumours were observed treatment was initiated with an
initial tail injection of 50 micrograms of either control siRNA
(control group) or human eIF5A1 siRNA (treated group). Control Mice
were subsequently treated by intra-tumoural injections 2 times per
week with PEI complexes containing pCpG-ms (empty vector, control
group; G-1, G-2, and G-3). Treated mice were subsequently treated
by intra-tumoural injections 2 times per week with PEI complexes
containing the RNAi-resistant plasmid pCpG-eIF5A1k50R (20 g plasmid
DNA) (treated group; G-4, G-5, and G-6). Control mice continued to
receive control siRNA (control group R-1, R-2, and R-3) by i.v.
injection once per week. Treated mice continued to receive human
eIF5A1 siRNA (20 .mu.g) (treated group R-4, R-5, and R-6) by i.v.
injection once per week. The data shown in FIG. 12 is the tumor
volume for all the mice in each group. Six intramural injections of
PEI/DNA (red arrows) and four i.v. injections of siRNA (blue
arrows) were given over a period of 21 days.
[0159] FIG. 13 provides an overlay of the results from Example 8
and 9. SCID mice were injected subcutaneously with KAS cells. The
data shown in FIG. 13 is the average tumor volume for the mice in
each group +/-standard error. Asterix denote statistical
significance between treated and control groups (**=p<0.01;
***=p<0.001; n=3).
Protocol for Forming PEI Complexes:
[0160] 1. Bring components to room temperature. Keep sterile.
[0161] 2. Dilute plasmid DNA or plasmid DNA+siRNA into a total
volume of 25 .mu.l. Use sterile water to adjust the volume. [0162]
a) For plasmid DNA only complexes: [0163] Dilute 20 .mu.g of
plasmid DNA (10 .mu.l at 2 mg/ml) into a total volume of 25 .mu.l.
Use sterile water to make up difference. [0164] b) For plasmid
DNA+siRNA complexes: [0165] Dilute 20 .mu.g of plasmid DNA (-10
.mu.l at 2 mg/ml) and 10 g of siRNA (10 .mu.l at 1 mg/ml) into a
total volume of 25 .mu.l. Use sterile water to make up difference.
[0166] 3. Adjust the volume of DNA solution to 50 .mu.l 5% glucose
by adding 25 .mu.l of 10% glucose (provided with PEI kit). Vortex
gently and centrifuge briefly. [0167] 4. Dilute in vivo JETPEI into
a total volume of 25 .mu.l of 10% glucose. [0168] a) For plasmid
DNA only complexes: [0169] Dilute 3.2 .mu.l of in vivo JETPEI into
a total volume of 25 .mu.l of 10% glucose. Adjust volume to 50
.mu.l with sterile water to end up with a final concentration of 5%
glucose. Vortex gently and centrifuge briefly. [0170] b) For
plasmid DNA+siRNA complexes: [0171] Dilute 4.8 .mu.l of in vivo
JETPEI into a total volume of 25 .mu.l of 10% glucose. Adjust
volume to 50 .mu.l with sterile water to end up with a final
concentration of 5% glucose. Vortex gently and centrifuge briefly.
[0172] 5. Immediately add 50 .mu.l of diluted PEI to the 50 .mu.l
of diluted DNA (do not reverse the order!). Vortex briefly and
immediately spin down. [0173] 6. Incubate for 15 minutes prior to
injection. Complexes are stable for 6 hours.
[0174] Regarding the tail-vein injection of siRNA, the initial
siRNA injection was 50 micrograms. siRNA was diluted to 0.4 mg/ml
in PBS. 125 .mu.l per mouse (50 .mu.g) was injected into the tail
vein. Subsequent injections of serum-stabilised siRNA were given
two times per week at 20 .mu.g per mouse. siRNA was diluted to 0.4
mg/ml in PBS. 50 .mu.l per mouse (20 .mu.g) was injected into the
tail vein.
[0175] FIG. 13B shows that co-administration of eIF5A1 plasmid and
eIF5A1 siRNA results in tumour shrinkage. SCID mice were injected
subcutaneously with KAS cells. Treatment was initiated when
palpable tumours were observed. Mice were injected intra-tumourally
2 times per week with PEI complexes containing the RNAi-resistant
plasmid pCpG-eIF5A1k50R and eIF5A1 siRNA (treated group; 0-4, G-5,
and G-6). Six injections over a period of 21 days were given.
Forty-two days after the initiation of treatment the mice were
sacrificed and the skin under the tumour site was opened and
examined for evidence of tumour growth. No tumour growth was
observed in any of the group 2A treated mice.
[0176] FIG. 13C shows that administration of eIF5A 1 siRNA
intra-venously (i.v.) and PEI/eIF5A1K50R plasmid complexes
intra-tumourally (i.t.) results in tumour shrinkage of multiple
myeloma subcutaneous tumours. SCID mice were injected
subcutaneously with KAS cells. When palpable tumours were observed
treatment was initiated with an initial injection of 50 micrograms
of human eIF5A1 siRNA (treated group). Mice were subsequently
treated by intra-tumoural injections 2 times per week with PEI
complexes containing the RNAi-resistant plasmid pCpG-eIF5A1k50R
(treated group; R-4, R-5, and R-6). Mice continued to receive human
eIF5A1 siRNA by i.v. injection once per week. Treatment ended 21
days after initiation of treatment. Forty-two days after the
initiation of treatment the mice were sacrificed and the skin under
the tumour site was opened and examined for evidence of tumour
growth. There was no evidence of tumour growth in one mouse of the
treatment group (group 2B).
Example 10
Intra-Venous Co-Administration of eIF5A1 Plasmid and eIF5A1 siRNA
Delays Growth of Multiple Myeloma Subcutaneous Tumours
[0177] SCID mice were injected subcutaneously with KAS cells. When
palpable tumours were observed treatment was initiated with an
initial injection of 50 micrograms of either control siRNA (control
group) or human eIF5A1 siRNA (treated group). Mice were
subsequently treated by intra-venous (red arrows) or
intra-peritoneal injections (green arrow).about.twice per week with
either PEI complexes containing pCpG-mcs (empty vector; control
group A1, A2, and A3) or PEI complexes containing the
RNAi-resistant plasmid pCpG-eIF5A1k50R (treated group; A4, A5, and
A6). Mice continued to receive either control siRNA (control group
A1, A2, and A3) or human eIF5A1 siRNA (treated group A4, A5, and
A6) by i.v. injection (blue arrows) once per week. The data shown
is the tumour volume for all the mice in each group. The data shown
in FIG. 14 is the tumour volume for all the mice in each group.
Example 11
Administration of eIF5A1 siRNA Intra-Venously (i.v.) and
PEI/eIF5A1K50R Plasmid Complexes Intra-Venously (i.v.) or
Intra-Peritoneal (i.p.) Delays Growth of Multiple Myeloma
Subcutaneous Tumours
[0178] SCID mice were injected subcutaneously with KAS cells. When
palpable tumours were observed treatment was initiated with an
initial injection of 50 micrograms of either control siRNA (control
group) or human eIF5A1 siRNA (treated group). Control mice were
subsequently treated by intra-venous or intra-peritoneal injections
once per week with PEI complexes containing pCpG-mcs (empty vector;
control group was three mice: B1, B2, and B3). Treated mice were
subsequently treated by intra-venous or intra-peritoneal
injections.about.once per week with PEI complexes containing the
RNAi-resistant plasmid pCpG-eIF5A1.sup.K50R (treated group; B4, B5,
and B6). Mice continued to receive either control siRNA (control
group B1, B2, and B3) or human eIF5A1 siRNA (treated group was
three mice: B4, B5, and B6) by i.v. injection once per week. The
experiment began with initial siRNA injection of 50 .mu.g (day-2 on
graph in FIG. 15). Subsequent injections used 20 micrograms of
siRNA once weekly. The siRNA was given naked, i.e. no delivery
vehicle. PEI complexes contained 20 .mu.g of plasmid DNA. The
initial PEI injection was given i.p. and subsequent injections were
given i.v. The data shown in FIG. 15 is the tumor volume for all
the mice in each group.
[0179] FIG. 16 provides an overlay of Example 10 and 1. SCID mice
were injected subcutaneously with KAS cells. Treatment was
initiated when palpable tumours were observed. One set of mice
received i.v. injections of either control siRNA (control; Group A)
or eIF5A1 siRNA (treated; Group A) once per week and either i.v. or
i.p. of either PEI complexes containing pCpG-mcs (control; Group A)
or PEI complexes containing the RNAi-resistant plasmid
pCpG-eIF5A1.sup.K50R (treated; Group A). A second set of mice were
given i.v. or i.p. injections.about.2 times per week with either
PEI complexes containing pCpG-mcs (empty vector) and control siRNA
(control; Group B.) or PEI complexes containing the RNAi-resistant
plasmid pCpG-eIF5A1k50R and eIF5A1 siRNA (treated; Group B). The
data shown is the average tumour volume for the mice in each group
+/-5 standard error. Asterix denote statistical significance
between treated and control groups (*=p<0.05; ***=p<0.001;
n=3).
[0180] The protocols for preparing the PEI complexes and the siRNA
are as described in previous examples.
Example 12
Co-Administration of eIF5A Plasmid and eIF5A1 siRNA Delays Growth
of Multiple Myeloma Subcutaneous Tumours and Results in Tumour
Shrinkage
[0181] SCID mice were injected subcutaneously with KAS cells.
Treatment was initiated when palpable tumours were observed.
Control mice were injected intra-tumourally 2 times per week with
PEI complexes containing pCpG-mcs (empty vector) and control siRNA
(control group had 3 mice: control 1, control 2, and control 3).
Treated mice were injected intra-tumourally 2 times per week with
PEI complexes containing the RNAi-resistant plasmid
pCpG-eIF5A1.sup.K50R and eIF5A1 siRNA (treated group contained 4
mice: 5A-1, 5A-2, 5A-3, and 5A-4). The intra-tumoral rejections of
PEI complexes contained both 20 ug of plasmid DNA and 10 .mu.g of
siRNA. The data shown in FIGS. 17A and 17B is the tumour volume for
all the mice in each group.
Example 13
Administration of eIF5A1 siRNA Intra-Venously (i.v.) and
PEI/eIF5A1.sup.K50R Plasmid Complexes Intra-Tumourally (i.t.)
Results in Tumour Shrinkage of Multiple Myeloma Subcutaneous
Tumours
[0182] SCID mice were injected subcutaneously with KAS cells. When
palpable tumours were observed treatment was initiated with an
initial injection of 50 micrograms of either control siRNA (control
group had three mice: control 1, control 2 and control 3) or human
eIF5A1 siRNA (treated group had 3 mice: 5A-1, 5A-2, 5A-3). Control
mice were subsequently treated by intra-tumoural injections 2 times
per week with PEI complexes containing pCpG-mcs (20 .mu.g) (control
group 1-3). Treated mice were subsequently treated by
intra-tumoural injections 2 times per week with PEI complexes
containing the RNAi-resistant plasmid pCpG-eIF5A.sup.K50R (20
.mu.g) (5A-1, 5A-2, 5A-3). Control mice continued to receive either
control siRNA (20 .mu.g) by tail vein i.v. injection twice per
week. Treated mice continued to receive human eIF5A1 siRNA (20
.mu.g) by tail vein i.v. injection twice per week. The injections
were give 48 hours prior to the intra-tumoural injections. The
siRNA was given as naked siRNA, i.e. no delivery vehicle. The data
shown in FIGS. 18A and 18B is the tumour volume for all the mice in
each group.
Example 14
Co-Administration of eIF5A1.sup.K50R Plasmid, Driven by Either the
EF1 or B29 Promoter, and eIF5A1 siRNA Delays Growth of Multiple
Myeloma Subcutaneous Tumours and Results in Tumour Shrinkage
[0183] SCID mice were injected subcutaneously with KAS cells.
Treatment was initiated when palpable tumours were observed. Mice
were injected intra-tumourally 2 times per week with PEI complexes
containing either control vector (G1 and G2) or an eIF5A1 plasmid
driven by either the B29 promoter (G3 and G4) or the EF1 promoter
(G5 and G6) and either control siRNA (G1, G3, G5) or h5A1 siRNA
(G2, G4, G6). The data shown is the average tumour volume
+/-standard error for each group. Note: the B29 promoter was
intended as a B-cell-specific promoter. However, although the B29
promoter/mCMV enhancer used in this study was found to drive high
expression of HA-eIF5A1.sup.K50R in KAS cells in vitro, it does not
appear to be B-cell-specific (likely due to CMV enhancer). See FIG.
19.
Example 15
Co-Administration of eIF5A1 siRNA Increases Anti-Tumor Effect of
eIF5A1.sup.K50R Plasmid, Driven by Either the EF1 or B29 Promoter,
on Multiple Myeloma Subcutaneous Tumours and Results in Reduced
Tumor Burden
[0184] SCID mice were injected subcutaneously with KAS cells.
Treatment was initiated when palpable tumours were observed. Mice
were injected intra-tumourally 2 times per week with PEI complexes
containing either control vector (G1 and G2) or an eIF5A1 plasmid
driven by either the B29 promoter (G3 and G4) or the EF1 promoter
(G5 and G6) and either control siRNA (G1, G3, G5) or h5A1 siRNA
(G2, G4, G6). The mice were sacrificed 24 days after the initiation
of treatment and the subcutaneous tumor was removed and weighed.
The data shown is the average tumor weight +/-standard error for
all groups. See FIG. 20.
Example 16
eIF5A1 siRNA Synergistically Increases Apoptosis Induction
Resulting from Infection with Ad-eIF5A in Lung Adenocarcinoma
Cells
[0185] A549 cells were infected with either Ad-LacZ or Ad-eIF5A.
Cells were transfected with either a control siRNA or an siRNA
targeting human eIF5A1 (h5A1) by adding the transfection media to
cells immediately following addition of the virus. Four hours after
transfection with the siRNA and infection with virus, the media was
replaced with fresh media and the cells were incubated for 72 hours
prior to labelling with Annexin/PI to detect apoptotic cells. Note:
over-expression of eIF5A in this cell line results in the
accumulation of unhypusinated eIF5A due to limiting amounts of DHS
and DOHH and therefore results in same pro-apoptotic effect as
over-expression of eIF5A.sup.K50R. These data indicate that the
synergistic effect in apoptosis caused by simultaneous suppression
of hypusinated eIF5A and over-expression of unhypusinated eIF5A is
observed in non-myeloma tumour-types as well. See FIG. 21.
Example 17
Construction of Plamsid pExp5A
[0186] pExp5A is an expression plasmid with reduced CpG
dinucleotides designed to drive expression of human eIF5A1.sup.K50R
predominantly in cells of B cell lineage. The vector is derived
from pCpG-LacZ, a plasmid completely devoid of CpG dinucleotides
(Invivogen). All the elements required for replication and
selection in E. coli are free of CpG dinucleotides. The original
CMV enhancer/promoter and LacZ gene from the CpG-LacZ vector have
been replaced with a human minimal B cell specific promoter
(B29/CD79b; Invivogen) and human eIF5A1.sup.K50R, respectively, in
order to drive B-cell specific expression of eIF5A1.sup.K50R. The
B29 DHS4.4 3' enhancer has been introduced into the plasmid
downstream of the eIF5A1 expression cassette in order to enhance
activity of the B29 promoter and reduce expression in non-B cells
(Malone et al. 2006. B29 gene silencing in pituitary cells is
regulated by its 3' enhancer. J. Mol. Biol. 362: 173-183).
Incorporation of the B29 minimal promoter, eIF5A1.sup.K50R, and the
B29 DHS4.4 3' enhancer has introduced 32 CpG dinucleotides into the
vector.
Elements for expression in E. coli Origin of replication: E. coli
R6K gamma ori. *Due to the presence of the R6K gamma origin of
replication, pCpG plasmids can only be amplified in E. coli mutant
strain expressing a pir mutant gene. They will not replicate in
standard E. coli strains. Therefore, pCpG plasmids are provided
with the E. coli GT115 strain, a pir mutant also deficient in Dcm
methylation (Invivogen). Bacterial promoter: EM2K, a CpG-free
version of the bacterial EM7 promoter. Selectable marker:
Zeocin.TM. resistance gene; a synthetic allele with no CpGs.
Elements for Expression in Mammalian Cells
[0187] Mammalian promoter: the human -167 bp minimal B29 (CD79b)
promoter for tissue-specific expression in B cells. A synthetic
intron (I 140) is also present in the 5'UTR. Polyadenylation
signal: a CpG dinucleotide-free version of the late SV40
polyadenylation signal. 3' Enhancer: the human B29 DHS4.4 3'
enhancer. MAR: Two CpG-free Matrix attached regions (MAR) are
present between the bacterial and mammalian transcription units.
One MAR is derived from the 5' region of the human IFN-f3 gene and
one from the 5' region of the 3-globin gene.
[0188] The predicted Sequence of pExp5A (3371 bp is provided at
FIGS. 23A and 23B.
TABLE-US-00003 Amino Acid Sequence of eIF5A1.sup.K50R
MADDLDFETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTSKT
GRFIGHAKVHLVGIDIFTGKKYEDICPSTHNMDVPNIKRNDFQLIGIQ
DGYLSLLQDSGEVREDLRLPEGDLGKEIEQKYDCGEEILITVLSAMTE EAAVAIKAMAK * K50R
mutation is underlined
Construction of pExp5A--Outline of Construction: Step 1: Cloning of
B29 DHS4.4 3' enhancer and subcloning into pGEM T easy
(Promega)--creates pGEM-4.4enh #8. Step 2: Subcloning of minimal
B29 promoter into pCpG-LacZ (Invivogen)--creates B29-5 #3. Step 3:
Subcloning of HA-eIF5A10R into B29-5#3 vector--creates
B29-5#3-eIF5A1.sup.K50R. Step 4: Creation of new multiple cloning
site in pCpG-mcs (Invivogen)--creates pCpG-Linker4. Step 5:
Subcloning of B29 DS4.4 3' enhancer into pCpG-Linker-4--creates
pCpG-DHS4.4. Step 6: Subcloning of B29
promoter+HA-eIF5A1.sup.K50R+SV40 pA expression cassette into
pCpG-DHS4.4 creates pExp-5. Step 7: Replacement of
HA-eIF5A1.sup.K50R in pExp-5 with non-HA eIF5A1 KOR creates final
vector, pExp5A.
Construction in Detail:
[0189] Step 1: Cloning of B29 DHS4.4 3' Enhancer and Subcloning
into pGEM T Easy (Promega)--Creates pGEM-4.4Enh #8.
[0190] The B29 DHS4.4 3' enhancer was cloned by PCR from genomic
DNA isolated from KAS cells (human multiple myeloma cell line)
using the following primers: forward 5'-CAGCAAGGGAGCACCTATG-3' and
reverse 5'-GTTGCAGTGAGCGGAGATG-3'. The primers were designed using
the sequence of the human CD79B/GH-1 Intergenic region (Accession
AB062674). The resulting 608 bp PCR fragment was subcloned into the
pGEM.RTM. T easy cloning vector (Promega) and sequenced. Komatsu et
al. 2002. Novel regulatory regions found downstream of the rat
B29/Ig-b gene. Eur. J. Biochem. 269: 1227-1236.
TABLE-US-00004 Sequence of B29 DHS4.4 3' enhancer PCR fragment (297
bp) in pGEM-4.4enh #8 ##STR00001## +4.4 regions contains several
transcription factor binding sites ##STR00002## ##STR00003##
##STR00004## ##STR00005##
TABLE-US-00005 Alignment of B29 DHS4.4 3' enhancer PCR fragment
(297 bp) in pGEM-4.4enh #8 with sequence of the human CD79B/GH-1
Intergenic region (Accession AB062674). 1 10 20 30 40 50 60 70
|--------+---------+---------+---------+---------+---------+---------+
GGGA CAGCTGCCAGCTGGGAGACCAAGTGC TC CCT CGTGCA C TCCCT CC CCAGC PCR
Consensus
****************************************************************-
****** 80 90 100 110 120 130
---------+---------+---------+---------+---------+---------|
CTGTGCTCCACTTCCTGTTGACCCTGG GGG TCCTTCGAGGCCCCTCTGCTATTCCT PCR
Consensus
************************************************************ 131
140 150 160 170 180 190 200
|--------+---------+---------+---------+---------+---------+---------+
CTCTGAATTCCAGCAGGGGAGCACCTATGCTGTGGGAGCTGCCAGTTT TGGGGA TCA GA
CAGCA PCR Consensus
****************************************************************-
****** 210 220 230 240 250 260
---------+---------+---------+---------+---------+---------|
CAGGGGAACTAGTG G AC GTGCCAATTTTC CC TTCCCTCTG TTCC GGTGG PCR
Consensus
************************************************************ 261
270 280 290 300 310 320 330
|--------+---------+---------+---------+---------+---------+---------+
GGCAGGTGGGTA GGCCCCC CGCCTGCAGTTTCAGGT TCTCTCCACC PCR ACC Consensus
************************************************ACC 340 350 360 370
380 390
---------+---------+---------+---------+---------+---------| PCR
Consensus 391 400 410 420 430 440 450 460
|--------+---------+---------+---------+---------+---------+---------+
PCR Consensus 470 480 490 500 510 520
---------+---------+---------+---------+---------+---------| PCR
Consensus 521 530 540 550 560 570 580 590
|--------+---------+---------+---------+---------+---------+---------+
PCR Consensus 600 610 620 630 640 650
---------+---------+---------+---------+---------+---------|
ACCTCTG ACACAGTTTCCCTGAGACTTTGA GCTCTTGTTTTATTTA PCR ACCTCT
Consensus ACCTCT********************************************* 651
660 670 680 690 700 710 720
|--------+---------+---------+---------+---------+---------+---------+
TTTATTTATTTATTTATTTACTTATTTATTTATTTGCAGACAGAGTCTCACTCTGTTGCCCAGACTG
PCR Consensus
****************************************************************-
****** 730 740 750 760 770 780
---------+---------+---------+---------+---------+---------|
TGCAGTGGCACCATCTCCGCTCACTGCAACCTCCGTCTCCTGAGTTCAAGCAATTCTCCT PCR
Consensus
************************************************************ 781
790 800 |--------+---------| GCCTCAGCCTCCAAAGTACC PCR Consensus
******************** indicates data missing or illegible when
filed
Step 2: Subcloning of Minimal B29 Promoter into pCpG-LacZ
(Invivogen--Creates B29-5 #3
[0191] The minimal -167 human B29 promotor was amplified from a
commercial plasmid bearing the full length human B29 promotor
(pDrive-hB29; Invivogen) using the following primers: forward
5'-CCAACTAGTGCGACCGCCAAACCTTAGC-3'; reverse:
5'-CAAAAGCTTGACAACGTCCGAGGCTCCTTGG-3'. The resulting PCR fragment
was digested with SpeI and HindIII and ligated into the SpeI and
HindIII sites of the pCpG-LacZ vector (Invivogen) to create B29-5
#3.
TABLE-US-00006 Sequence of B29 minimal promoter PCR fragment (188
bp) in B29-5 #3
GCGACCGCCAAACCTTAGCGGCCCAGCTGACAAAAGCCTGCCCTCCCCCAGG
GTCCCCGGAGAGCTGGTGCCTCCCCTGGGTCCCAATTTGCATGGCAGGAAGG
GGCCTGGTGAGGAAGAGGCGGGGAGGGGACAGGCTGCAGCCGGTGCAGTTA
CACGTTTTCCTCCAAGGAGCCTCGGACGTTGTC Alignment of B29 minimal promoter
PCR fragment (B29_min) in B29-5 #3 with full length human B29
promoter from pDrive-hB29 1 10 20 30 40 50 60 70
|--------+---------+---------+---------+---------+---------+---------+
B29_prom
CCTGCAGGGCCCACTAGTAAACGGAGGGTTGTAAGGAGAGTGAGAGGTGGACAGAGGGCACCGAC-
GATTT B29_min Consensus
****************************************************************-
****** 80 90 100 110 120 130
---------+---------+---------+---------+---------+---------|
B29_prom AGCATCTCTTCCTCTCCTGGGGGTCA GGATGAGAGACAAAAAGAAGCTGCCAGG
AAAC B29_min Consensus
************************************************************ 131
140 150 160 170 180 190 200
|--------+---------+---------+---------+---------+---------+---------+
B29_prom ATA ATTCAGAGGGCTC CTGC CTGAGGTCTGCAAGCATGCTGTGTACACTTGT
CATGTTGTT B29_min Consensus
****************************************************************-
****** 210 220 230 240 250 260
---------+---------+---------+---------+---------+---------|
B29_prom CCCTGCACAAGGGCATCTCTGAAGGGGCTGCACTGGACCCA AGGGGCGCAAAGGT
B29_min Consensus
************************************************************ 261
270 280 290 300 310 320 330
|--------+---------+---------+---------+---------+---------+---------+
B29_prom GAGTTTATATCAGTTCCTGAGCACTGTGGCTCCATCCAGCACTCTGAGGAC A
ATACAGCTGGAG B29_min Consensus
****************************************************************-
****** 340 350 360 370 380 390
---------+---------+---------+---------+---------+---------|
B29_prom GACCTGAGGGCT A A AGCTCCTGTTCCCTGCCC AGACCCCCTGGACCTGCAG
B29_min Consensus
************************************************************ 391
400 410 420 430 440 450 460
|--------+---------+---------+---------+---------+---------+---------+
B29_prom ACAACAATTCAACGCACTCAGAGTCCCACAGTTAGGAACTCCCTG
GCCCCCAGTGGCTGCGT T B29_min Consensus
****************************************************************-
****** 470 480 490 500 510 520
---------+---------+---------+---------+---------+---------|
B29_prom GGATTTTCGCA
GCTGTCTCCACCTACATCCACCCTGTTTGGCAGCCCCTACATACTCT B29_min Consensus
************************************************************ 521
530 540 550 560 570 580 590
|--------+---------+---------+---------+---------+---------+---------+
B29_prom TTCA CATGAGGAAGGGAGGCCTCTC CC AGACCTGG CT
TCTTCTCCCAGTGGCTGCCAC CC B29_min Consensus
****************************************************************-
****** 600 610 620 630 640 650
---------+---------+---------+---------+---------+---------|
B29_prom TGACCTGCTCTTGCTCC CCTCTGTGGCTCCC CCACAGGGTCAACTTCCAAC
B29_min Consensus
************************************************************ 651
660 670 680 690 700 710 720
|--------+---------+---------+---------+---------+---------+---------+
B29_prom ATGGCTGCCTGCACTCCAGCCAAGAGGCTCTGCTCTGGGCCCCTCCAGATGCCT
CCTGGGTCTGT C B29_min Consensus
****************************************************************-
****** 730 740 750 760 770 780
---------+---------+---------+---------+---------+---------|
B29_prom TGCCCTGTCCTTCTTCAGTGCTCCTCTTCCCGCTGGGTG GGAATAGTTCAGGAC
B29_min Consensus
************************************************************ 781
790 800 810 820 830 840 850
|--------+---------+---------+---------+---------+---------+---------+
B29_prom GCTAAGTTCAGGTTCATTC TAGGACAGGTGCCTATTTCGCTCACGGCCC T
GACTTGCCGG B29_min Consensus
****************************************************************-
****** 860 870 880 890 900 910
---------+---------+---------+---------+---------+---------|
B29_prom GCTCGGCCCTTCGGGGAGTT GCAGAC C GAGG CTGGCTGGCCCAGGG T
B29_min Consensus
************************************************************ 911
920 930 940 950 960 970 980
|--------+---------+---------+---------+---------+---------+---------+
B29_prom CCACCGGTGGGGTAAGCACAGACAG GGGG GCACAGGCTTCCCCCAGGA
ACTGAGAGGCCCCCCAGAG B29_min Consensus
****************************************************************-
****** 990 1000 1010 1020 1030 1040
---------+---------+---------+---------+---------+---------|
B29_prom GCATCCACAGAGGACCCCAGCTGTGCTGCCCA CTGG GACC CCTT C B29_min
GCG CC CCTT AC C Consensus **************************************GC
CCTTA 1041 1050 1060 1070 1080 1090 1100 1110
|--------+---------+---------+---------+---------+---------+---------+
B29_prom B29_min Consensus 1120 1130 1140 1150 1160 1170
---------+---------+---------+---------+---------+---------|
B29_prom B29_min Consensus 1171 1180 1190 1200 1210 1220 1230 1237
|--------+---------+---------+---------+---------+---------+------|
B29_prom B29_min Consensus C******************************
indicates data missing or illegible when filed
Step 3: Subcloning of HA-eIF5A1.sup.K50R into B29-5#3
Vector--Creates pB329-eIF5A1K50R.sub.--7.
[0192] HA-eIF5A1.sup.K50R was amplified by PCR using the
pHM6-eIF5A1.sup.K50R as a DNA template and the following primers:
forward 5'-CGCCATGGACATGTACCCTACGACGTCCCAGACTACGCTGCAGATGATTTG
GACTTCGAG-3' and reverse 5'-CGCGCTAGCAGTTATTTGCCATCGCC-3'. The
resulting PCR fragment was digested with NcoI and NheI and
subcloned into the NcoI and NheI sites of B29-5 #3 to replace
LacZ.
TABLE-US-00007 Sequence of HA-eIF5A1.sup.K50R PCR fragment (497 bp)
in pB29-eIF5A1K50R_7
ACATGTACCCTTACGACGTCCCAGACTACGCTGCAGATGATTTGGACTTCGAG
ACAGGAGATGCAGGGGCCTCAGCCACCTTCCCAATGCAGTGCTCAGCATTAC
GTAAGAATGGTTTTGTGGTGCTCAAGGGCCGGCCATGTAAGATCGTCGAGAT
GTCTACTTCGAAGACTGGCAGGCATGGCCATGCCAAGGTCCATCTGGTTGGC
ATTGATATTTTTACTGGGAAGAAATATGAAGATATCTGCCCGTCGACTCATAA
CATGGATGTCCCCAACATCAAAAGGAATGATTTCCAGCTGATTGGCATCCAG
GATGGGTACCTATCCCTGCTCCAGGACAGTGGGGAGGTACGAGAGGACCTTC
GTCTGCCTGAGGGAGACCTTGGCAAGGAGATTGAGCAGAAGTATGACTGTGG
AGAAGAGATCCTGATCACAGTGCTGTCCGCCATGACAGAGGAGGCAGCTGTT
GCAATCAAGGCGATGGCAAAATAACTG Translation of HA-eIF5A1.sup.K50R PCR
fragment in pB29-eIF5A1K50R_7 HA epitope eIF5A1.sup.K50R K50R
MDMYPYDVPDYAADDLDFETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVE
MSTSKTGRHGHAKVHLVGIDIFTGKKYEDICPSTHNMDVPNIKRNDFQLIGIQDG
YLSLLQDSGEVREDLRLPEGDLGKEIEQKYDCGEEILITVLSAMTEEAAVAIKAM AK
Alignment of HA-eIF5A1.sup.K50R PCR fragment in pB29-eIF5A1K50R_7
with human eIF5A1 (Accession # NP_001961) 1 10 20 30 40 50 60 70
|--------+---------+---------+---------+---------+---------+---------+
eIF5A HA-5A_K50R Consensus *********** 80 90 100 110 120 130
--------+---------+---------+---------+---------+---------| eIF5A
HA-5A_K50R Consensus 131 140 150 160 165
|--------+---------+---------+----+ eIF5A HA-5A_K50R Consensus
indicates data missing or illegible when filed
Step 4: Creation of New Multiple Cloning Site in pCpG-Mcs
(Invivogen)--Creates pCpG-Linker4.
[0193] The pCpG cloning vector, pCpG-mcs G2 (Invivogen), was
digested with EcoRI to remove the mammalian expression cassette
containing the mCMV enhancer, the hEF1 promoter, the synthetic
intron, the multiple cloning site, and the SV40 polyadenylation
signal. The EcoRI-digested pCpG-mcs G2 vector was then ligated to a
synthetic linker with EcoRI sticky ends to create a promoterless
vector with a new multiple cloning site (pCpG-Linker4).
##STR00006##
TABLE-US-00008 Sequence of region surrounding new multiple cloning
site in pCpG-Linker4 ##STR00007## ##STR00008##
Step 5: Subcloning of B29 DS4.4 3' Enhancer into
pCpG-Linker--4-Creates pCpG-DHS4.4.
[0194] The B29 DHS4.4 3' enhancer was amplified by PCR using
pGEM-4.4enh #8 as a template and the following primers: forward
5'-GAAGCGGCCGCACCACCCTGGGCCAGGCTGG-3'; and reverse
5'-CCACGCGTAGAGGTGTTAAAAAGTCITTfAGGTAAAG-3'. The resulting PCR
fragment was digested with NotI and MluI and ligated into the NotI
and MluI sites in the new multiple cloning site of pCpG-Linker4 to
create pCpG-DHS4.4.
TABLE-US-00009 >pCpG-DHS4.4 full-length sequences (2,282 bp)
##STR00009## ##STR00010## ##STR00011## ##STR00012##
Step 6: Subcloning of B29 Promoter+HA-eIF5A1.sup.K50R+SV40 pA
Expression Cassette into pCpG-DHS4.4-Creates pExp-5.
[0195] The B29-eIF5A1 expression cassette containing the minimal
B29 promoter, the synthetic intron, HA-eIF5A1.sup.K50R, and the
SV40 pA, was amplified from pB29-eIF5A1K50R.sub.--7 (Step 3) by PCR
using the following primers: forward
5'-GTTATCGATACTAGTGCGACCGCCAAACC-3'; and reverse
5'-CAAGCGGCCGCCATACCACATTGTAGAGAGTTTTAC-3'. The resulting PCR
fragment was digested with ClaI and NotI and subcloned into the
ClaI and NotI sites in the multiple cloning site of pCpG-DHS4.4 to
create pExp-5.
Step 7: Replacement of HA-eIF5A1.sup.K50R in pExp-5 with non-HA
eIF5A1.sup.K50R Creates Final Vector, pExpSA.
[0196] The pExp-5 plasmid was digested with NcoI and NheI to remove
HA-eIF5A1.sup.K50R. A non-HA-tagged eIF5A1.sup.K50R PCR fragment
was amplified from pHM6-eIF5A1.sup.K50R by PCR using the following
primers: forward 5'-CACCATGGCAGATGATTTGGACTTC-3'; and reverse
5'-CGCGCTAGCCAGTTATTTTGCCATCGCC-3'. The resulting PCR product was
digested with NcoI and NheI and ligated into the NcoI and NheI
sites of B29-5 #3 to generate B29-K50R. B29-K50R was digested with
NcoI and NheI and the 470 bp eIF5A1.sup.K50R fragment was gel
purified and ligated to NcoI/NheI-digested pExp-5 to generate the
final expression vector, pExp5A.
Example 18
Testing of pExp5A
[0197] Various cell lines were transfected with plasmids using
Lipofectamine 2000 and expression of HA-eIF5A1K5OR was determined
24 hours following transfection by Western blotting with an anti-HA
antibody (Roche). Different cells lines tested were P3X63Ag8.653
(mouse B lymphoblast--myeloma), KAS (hyman myeloma), HepG2 (huma
liver hepatocellular carcinoma), T24 (human bladder carcinoma);
HT-29 (human colorectal adenocarcinoma), HEK-293 (human embryonic
kidney cells), PC3 (human prostrate adenocarcinoma); HeLa (human
cervical adenocarcinoma), and A549 (lung carcinoma). See FIGS. 24A
and 24B.
[0198] pExp-5 plasmid expresses HA-eIF5A1.sup.K50R in both human
and mouse myeloma cell lines at comparable levels to a plasmid with
the constitutive EF1 promoter (CpG-eIF5A1.sup.K50R). However
expression of HA-eIF5A1.sup.K50R driven by pExp-5 is limited in
non-B cell lines compared to expression by a constitutive promoter.
The one exception was in HEK-293 cells, a human embryonic kidney
cell line where high levels of HA-eIF5A1.sup.K50R expression was
observed following pExp-5 transfection--this may be due to 15 the
embryonic nature of the cell line; at this time we do not know if
pExp-5 expresses in adult kidney cells. The final plasmid for use
in toxicity studies and clinical trial will be a version of pExp-5
in which HA-eIF5A1.sup.K50R has been replaced by non-HA tagged
eIF5A1.sup.K50R (pExp5A). pExp-5 contains HA-tagged eIF5A1.sup.K50R
under the control of the minimal human B29 promoter/enhancer;
expression of HA-eIF5A1.sup.K50R was compared to that driven by
plasmids with constitutive expression as well as to a plasmid
containing the full-length B29 promoter
Example 19
Formation of In Vivo JETPEI.TM. Nanoparticle
[0199] This example given is for formation of the in vivo
JETPEI.TM. nanoparticle complex for injection into 20 g mouse for a
dose of 1.5 mg/kg (0.1 mL)--1.5 mg/kg=1.0 mg pExp5A/kg+0.5 mg
h5A1/kg--DNA:siRNA ratio=2:1.
[0200] Dilute plasmid DNA and siRNA into a total volume of 25 ml.
Use sterile water to adjust the volume. * Dilute 20 mg of plasmid
DNA (10 ml at 2 mg/ml) and 10 mg of siRNA (10 ml at 1 mg/ml) into a
total volume of 25 ml. Use sterile water to make up difference.
Adjust the volume of DNA solution to 50 ml 5% glucose by adding 25
ml of 10% glucose (provided with PEI kit). Vortex gently and
centrifuge briefly. Dilute in vivo JETPEI.TM. into a total volume
of 25 ml of water. * Dilute 3.6 ml of in vivo JETPEI.TM. into a
total volume of 25 ml of water. Adjust final volume to 50 ml with
10% glucose to end up with a final concentration of 5% glucose.
Vortex gently and centrifuge briefly. Immediately add 50 ml of
diluted PEI to the 50 ml of diluted DNA (do not reverse the
order!). Vortex briefly and immediately spin down.
[0201] After formation the complex is stable for 8 to 10 hours. The
N/P ratio of the complex should be 6. The N/P ratio is the ratio of
the number of positively charged nitrogen residues of in
vivo-jetPEI to the number of negatively charged phosphate residues
of DNA and siRNA. DNA and siRNA contain the same number of
phosphate groups per gram. The N/P ratio is therefore a measure of
the ionic balance within the complex. Increasing the N/P ratio of
the complex can increase the toxicity of the complex. In vivo
JET-PEI is provided as a 150 mM solution (expressed as nitrogen
residues) while DNA contains 3 nmoles of anionic phosphate in 1 mg.
The final concentration of DNA in the final volume should not
exceed 0.5 mg/ml. The DNA should be of high quality and prepared in
water. In vivo-jetPEI and 10% glucose should be brought to room
temperature prior to use.
Example 20
Dose Range-Finding and Repeat Dose Studies with Intra-Venous SNS01
and SNS-EF1/UU in Mice
[0202] SNS01 is one embodiment of the present invention--it is a
cancer therapy biologic targeted to the treatment of multiple
myeloma. SNS01 is comprised of three components: a DNA vector
expressing a pro-apoptotic mutant of eIF5A (see FIG. 22); an siRNA
that targets the native eIF5A that promotes growth/anti-apoptosis
of cancer cells (see the sequence in FIG. 25); and a synthetic
polymer called polyethylenimine (In vivo-jetPEI; Polyplus
Transfection Inc.) that acts as a delivery vehicle.
[0203] The purpose of the studies was to determine the maximum
tolerated dose and the feasibility of long-term administration of
therapeutic doses of intra-venous SNS01 into mice. Two separate
studies were performed. The maximum tolerated dose (Study ID: MTD)
study was an 8-day study in which mice received two intra-venous
doses of increasing amounts of SNS01 (from 2.2 mg/kg to 3.7 mg/kg)
and toxicity was assessed by monitoring clinical signs, body
weight, organ weight and liver enzymes. The 9-week repeated dose
study (Study ID: EX6) was a study designed to assess toxicity
following long-term administration of twice-weekly therapeutic
doses (1.5 mg/kg) of SNS-EF1/UU and as well as it's various
components. SNS-EF1/UU is a preclinical version of SNS01 and
differs mainly in that expression of eIF5A.sup.K50R is driven by a
constitutive promoter (one that expresses in all tissues at all
times) rather than a B-cell-specific promoter as in the SNS01
complex. The use of the B cell-specific B29 promoter in SNS01 was
designed to enhance the safety of the therapeutic by limiting
expression of the pro-apoptotic eIF5A mutant to cells of B-cell
origin, including myeloma cells. The EX6 study also included a
group of mice that were dosed with a mouse-specific eIF5A siRNA to
determine whether there were any toxic effects of suppressing eIF5A
in mouse tissues. Toxicity in the repeated dose study was assessed
by monitoring clinical signs, body weight, hematology, liver
enzymes, as well as histopathology.
TABLE-US-00010 Animal Injection Duration of Study ID Model Schedule
Treatment Test Article MTD CD-1 Twice weekly 8-Days SNS01 (female)
Intra-venous (2 injections) EX6 Balb/c Twice weekly 9-Weeks
SNS-EF1/UU (female) Intra-venous SNS-EF1/UU components tested
individually Mouse eIF5A siRNA
TABLE-US-00011 Test Article Plasmid DNA siRNA Vehicle Material
Grade SNS01.sup.a pExp5A.sup.c eIF5A siRNA In vivo-jetPEI .TM.
GLP-grade (eIF5A.sup.K50R (dTdT overhang.sup.d) materials
expression driven human-specific by B29 B-cell- eIF5A siRNA
specific promoter) SNS-EF1/UU.sup.b pCpG-HA- h5A1 In vivo-jetPEI
.TM. Research-grade eIF5A.sup.K50R (UU overhang.sup.d) materials
(HA-eIF5A.sup.K50R human-specific expression driven eIF5A siRNA
ubiquitous EF1 promoter) .sup.aSNS01 contains GLP-grade materials
and is being developed for the clinic .sup.bSNS-EF1/UU is a test
article used in preclinical research that led to the development of
SNS01 .sup.cthe pExp5A plasmid is RNAi-resistant due to the fact
that the plasmid contains only the open reading frame of eIF5A
while the eIF5A siRNA (h5A1) targets the 3' UTR of eIF5A .sup.dthe
sequence of the SNS01 eIF5A siRNA and the h5A1 siRNA are identical
except for the presence of a dTdT overhang rather than a UU
overhang on the 3' terminal ends of the siRNA; the dTdT overhang
does not affect the target selectivity or efficacy of the siRNA but
has been proposed to enhance stability
[0204] Preclinical experiments have indicated that SNS01 is
therapeutic at doses of 0.75 mg/kg to 1.5 mg/kg (Study EX9). In the
8-day dose range-finding study (Study ID: MTD) significantly higher
doses than the therapeutic range was tested to determine the upper
limit of the dose range. Twice-weekly intra-venous doses of the
test article was well tolerated at the lower dose levels of 2.2
mg/kg and 2.9 mg/kg although one mouse reached morbidity at the 2.9
mg/kg and was euthanized. Doses at 3.3 mg/kg or above resulted in
survival rates of approximately 20-25%. Therefore, the maximum
tolerated dose is between 2.2 mg/kg and 2.9 mg/kg and is well above
the therapeutic range of 0.75 mg/kg to 1.5 mg/kg.
[0205] In the 9-week repeated dose study (Study ID: EX6) the mice
received twice weekly tail vein injections of therapeutic doses
(1.5 mg/kg) of SNS-EF1/UU and no test article-related toxic effects
were observed over the period of the study. The DNA and siRNA were
also tested separately in this study and both were well tolerated
by the mice. Since the human eIF5A siRNA is not active in mice, a
mouse eIF5A-specific siRNA was also included in this study. No
toxic effects related to chronic administration of the mouse eIF5A
siRNA were observed over the 9-week period. These results indicate
that therapeutic doses of SNS01 and SNS-EF1/UU are non-toxic to
mice even when administered over long periods.
TABLE-US-00012 Test Article and Vehicle Manufacturer of
Manufacturer of Plamid DNA siRNA Manufacturer of Formation of Test
Test Article component component PEI component Article SNS01 VGXI
Avecia Polyplus Components were Lot # Transfection Inc combined
with pExp5A.08L007 GLP-Grade 10% glucose to form nano- complexes;
complexes were injected within 2-4 hours SNS-EF1/UU Qiagen EndoFree
ThermoScientific Polyplus Components were Plasmid Mega Kit
Dharmacon RNAi Transfection Inc, combined with <0.1 EU/.mu.g DNA
Technologies Research-Grade 10% glucose to form nano- complexes;
complexes were injected within 2-4 hours Storage -20.degree. C.
-20.degree. 4.degree. Room Conditions (.gtoreq.1 year) (.gtoreq.1
year) (.gtoreq.1 year) Temperature (Stability) (.gtoreq.6
hours)
Test Systems and Study Designs
[0206] All aspects of this study were conducted in accordance with
the guidelines set out by the University of Waterloo Animal Care
Committee (Waterloo, Ontario, Canada) as established by the
Canadian Council on Animal Care and the Province of Ontario Animals
for Research Act. The CD-1 and BALB/c mice were obtained from
Charles River Laboratories (Quebec, Canada). Mice from both studies
received the test article twice-weekly via tail vein intra-venous
injections. Slow injections (.about.2-3 minutes) were used to
deliver volumes greater than 0.2 ml. The mice for the 8-day study
were approximately 6-9 weeks old at the start of study. The mice
for the 9-week repeated dose study were approximately 5-6 weeks old
at the initiation of the study.
TABLE-US-00013 STUDY ID: MTD No. Dose Animals Test N/P level
Injection Total # Group (female) Article ratio.sup.a (mg/kg) Volume
injections MTD-C 5 5% -- -- 0.33 mL 2 Glucose MTD-PA 5 SNS01 6 2.2
mg/kg 0.20 mL 2 MTD-PB 5 SNS01 6 2.9 mg/kg 0.27 mL 2 MTD-PC 4 SNS01
6 3.3 mg/kg 0.30 mL .sup. 1.sup.b MTD-PD 5 SNS01 6 3.7 mg/kg 0.33
mL .sup. 1.sup.b .sup.aN/P ratio = ratio of positively-charged
nitrogens on PEI to the negatively-charged phosphate groups of the
nucleic acids .sup.bdue to toxicity the surviving mice were not
given a second injection
TABLE-US-00014 STUDY ID: EX6 No. Dose Animals Test N/P level
Injection Total # Group (female) Article ratio (mg/kg) Volume
injections Ex6-G1 4 5% -- -- 0.10 mL 20 Glucose Ex6-G2 5 Vehicle 8
1.5 mg/kg 0.10 mL 20 Control.sup.a Ex6-G3 5 siRNA.sup.b 8 1.5 mg/kg
0.10 mL 20 Ex6-G4 6 DNA.sup.c 8 1.5 mg/kg 0.10 mL 20 Ex6-G5 4
SNS-EF1/ 8 1.5 mg/kg 0.10 mL 20 UU Ex6-G6 6 Mouse 8 1.5 mg/kg 0.10
mL 20 siRNA.sup.d .sup.aPEI complex containing a non-expressing
plasmid (same vector background as pExp5A) and a non-targeting
siRNA .sup.bPEI complex containing a non-expressing plasmid (same
vector background as pExp5A) and tne h5A1 siRNA .sup.cPEI complex
containing pCpG-HA-eIF5A.sup.K50R plasmid and a non-targeting siRNA
.sup.dPEI complex containing a non-expressing plasmid (same vector
background as pExp5A) and a mouse-specific eIF5A siRNA (the human
eIF5A siRNA is not active in mouse)
8-Day Maximum Tolerated Dose Study (MTD)
[0207] The two-dose 8-day study was a dose range-finding study
designed to determine the maximum tolerated dose of SNS01. The dose
range was 2.2 mg/kg to 3.7 mg/kg and is well above the therapeutic
dose range of 0.75 mg/kg to 1.5 mg/kg. At the lowest dose (2.2
mg/kg) of SNS01 no clinical signs of toxicity were observed except
for one mouse that exhibited slightly ruffled fur and decreased
activity that resolved within one hour. No clinical signs of
toxicity were observed following the 2.sup.nd injection of 2.2
mg/kg of SNS01. All the mice maintained their weight throughout the
study. No macroscopic changes in the organs were observed. The
organ weight to body weight ratios were unchanged from the control
group except for a modest increase in the ratio of the liver
weight:body weight ratio. However, since an increase in this ratio
was not observed in any of the higher dose level groups it is
unlikely to be related to the test article.
[0208] Four out of five mice tolerated 2.9 mg/kg of SNS01 with no
clinical signs of toxicity. However, one mouse experienced
convulsions and mild respiratory distress within 1 hour of
injection and had to be humanely euthanized. No clinical signs of
toxicity were observed following the 2.sup.nd injection of SNS01 in
the remaining mice. The mice maintained their weight throughout the
study and no macroscopic changes in the organs or changes in the
organ weight to body weight ratios were observed. There was a
slight increase in the serum levels of ALT following two doses of
2.9 mg/kg SNS01.
[0209] As expected, doses of SNS01 at or above 3.3 mg/kg were not
well tolerated and in both groups all mice but one had to be
humanely euthanized. In all cases where mice were humanely
euthanized due to morbidity the clinical signs appeared within 1
hour of injection and were consistent with other reported studies
using high doses of PEI. The surviving mice of the 3.3 mg/kg and
3.7 mg/kg recovered completely within 4 hours after the injection
and maintained their weight throughout the study, although they did
not receive a 2.sup.nd dose. The maximum tolerated dose of SNS01
therefore appears to be between 2.2 mg/kg and 2.9 mg/kg.
9-Week Repeated Dose Study (EX6)
[0210] The purpose of the 9-week repeated dose study was to assess
the safety of chronic administration of therapeutic doses (1.5
mg/kg) of SNS-EF1/UU, a complex that was used for preclinical
studies during development of SNS01. SNS-EF1/UU does not differ
significantly from SNS01, the major difference being that the
materials are research-grade and that eIF5A.sup.K50R expression is
driven by the constitutive human EF1 promoter that is active in all
cell types. Although SNS01 uses a B-cell-specific promoter to drive
eIF5A.sup.K50R expression, the use of a constitutive promoter in
this safety study allows for the assessment of toxicity resulting
from the accumulation of the mutant eIF5A.sup.K50R protein in
non-B-cell tissues. Another aspect of the 9-week repeated dose
study was the inclusion of groups to test the safety of the
individual components of SNS-EF1/UU. The DNA group (Ex6-G3) was
dosed with a complex containing the eIF5A plasmid and a
non-targeting control siRNA while the siRNA group (Ex6-G4) was
dosed with a complex containing the human eIF5A (h5A1) siRNA and a
non-expressing plasmid. Since the test article SNS-EF1/UU contains
a human eIF5A siRNA that will not affect expression of the
endogenous mouse eIF5A. another feature of this study was the
inclusion of a group (Ex6-G6) that was dosed with PEI complexes
containing a non-expressing plasmid and an siRNA that efficiently
targets mouse eIF5A. This group allowed assessment of the safety of
chronic administration of an active eIF5A siRNA.
[0211] All animals survived to the scheduled sacrifice date. No
clinical signs of toxicity were observed in any of the groups over
the course of the 9-week study and the mice in all groups continued
to gain weight during the study period. Red and white blood cell
counts were measured three and six weeks after the initiation of
treatment and were normal for all dosing groups. Serum liver enzyme
levels were measured following sacrifice and were within the normal
range for all mice. No changes in the macroscopic appearance of the
organs were observed in any of the groups. Histopathological
analysis of the major organs was conducted by an independent
pathologist (and revealed no toxicity attributable to the test
article.
[0212] Chronic administration of therapeutic doses of SNS-EF1/UU is
well tolerated by mice and no adverse effects were observed. In
addition, chronic administration of a mouse-specific eIF5A siRNA
revealed no toxic effects, indicating that the administration of
PEI complexes containing a human eIF5A siRNA should be safe for
humans.
Example 21
Therapeutic Efficacy Studies with Intra-Venous SNS-B29/UU and SNS01
in Multiple Myeloma Tumour-Bearing Mice
[0213] SNS01 is as described above. The test article SNS-B29/UU is
a preclinical version of SNS01. SNS-B29/UU differs very little from
SNS01, the chief difference being that the components are of
research-grade rather than GLP-grade. The purpose of the study
reported here was to determine the minimum effective dose of
SNS-B29/UU and to confirm that the GLP-grade materials that
comprise SNS01 perform as well as the research-grade materials that
were used for the preclinical studies. The repeated dose tumour
study (Study ID: EX9) was a 5-week study in which the ability of
increasingly smaller twice-weekly doses of SNS-B29/UU to inhibit
subcutaneous tumour growth in mice was assessed in order to
determine the optimal therapeutic dose of SNS01. The treated
animals were also assessed for signs of toxicity by monitoring
clinical signs, body weight and organ weight.
TABLE-US-00015 Injection Duration of Study ID Animal Model Schedule
Treatment Test Article Ex9 C.B17 (SCID) Twice weekly 35 Days
SNS-B29/UU (female) mice Intra-venous bearing Twice weekly 25 Days
SNS01 subcutaneous Intra-venous human multiple myeloma tumours
(KAS-6/1)
TABLE-US-00016 Test Article Plasmid DNA siRNA Vehicle Material
Grade SNS01.sup.a pExp5A.sup.c eIF5A siRNA.sup.d In vivo-jetPEI
.TM. GLP-grade (eIF5A.sup.K50R (dTdT overhang.sup.c) materials
expression driven human-specific by B29 B-cell- eIF5A siRNA
specific promoter) SNS-B29/UU.sup.b pExp5A.sup.c h5A1 In
vivo-jetPEI .TM. Research-grade (UU overhang.sup.c) materials
human-specific eIF5A siRNA .sup.aSNS01 contains GLP-grade materials
and is being developed for the clinic .sup.bSNS-B29/UU is a test
article used in preclinical research that led to the development of
SNS01 .sup.cthe pExp5A plasmid is RNAi-resistant due to the fact
that the plasmid contains only the open reading frame of eIF5A
while the eIF5A siRNA (h5A1) targets the 3' UTR of eIF5A .sup.dthe
sequence of the eIF5A siRNA and the h5A1 siRNA are identical except
for the presence of a dTdT overhang rather than a UU overhang on
the 3' terminal ends of the siRNA; the dTdT overhang does not
affect the target selectivity or efficacy of the siRNA but has been
proposed to enhance stability
[0214] The therapeutic range of SNS-B29/UU was determined in SCID
mice bearing subcutaneous human multiple myeloma tumours. Doses of
SNS-B29/UU between 0.15 mg/kg and 1.5 mg/kg were tested. The
anti-tumoural efficacy of the test article was determined by
twice-weekly tumour volume measurements and by excising and
weighing tumour tissue following sacrifice. SNS-B29/UU doses of
0.75 mg/kg and 1.5 mg/kg resulted in significant tumour shrinkage
indicating that the therapeutic range of SNS-B29/UU lies between
0.75 mg/kg and 1.5 mg/kg. Effective inhibition of growth of
subcutaneous tumours was also observed at 0.38 mg/kg SNS-B29/UU
although no tumour shrinkage was observed. Some inhibition of
tumour growth was even observed at doses as low as 0.15 mg/kg
SNS-B29/UU indicating a broad therapeutic range. See FIGS. 26 and
27.
[0215] The efficacy of SNS01 made using GLP-grade components was
compared to SNS-B29/UU and was found have a comparable efficacy in
the inhibition of tumour growth. Treatment of tumour-bearing SCID
mice with SNS01 and SNS-B29UU was well tolerated and the mice
continued to gain weight throughout the study.
TABLE-US-00017 Test Article and Vehicle Manufacturer of
Manufacturer of Plasmid DNA siRNA Manufacturer of Formation of Test
Test Article component component PEI component Article SNS01 VGXI
Avecia Polyplus Components were Lot # Transfection Inc combined
with pExp5A.08L0007 GLP-Grade 10% glucose to form nano- complexes;
complexes were injected within 2-4 hours SNS-B29/UU Qiagen EndoFree
ThermoScientific Polyplus Components were Plasmid Mega Kit
Dharmacon RNAi Transfection Inc. combined with <0.1 EU/.mu.g DNA
Technologies Research-Grade 10% glucose to form nano- complexes;
complexes were injected within 2-4 hours Storage -20.degree. C.
-20.degree. 4.degree. Room Conditions (.gtoreq.1 year) (.gtoreq.1
year) (.gtoreq.1 year) Temperature (Stability) (.gtoreq.6
hours)
Test Systems and Study Design
[0216] The female C.B.17/IcrHsd-Prkdc (SCID) mice were obtained
from Harlan (Indianapolis, Ind., USA). Subcutaneous tumours were
established by injecting 10.times.10.sup.6 viable KAS-6/1 (human
multiple myeloma) cells into the right flank of 5 to 6 week-old
mice. Treatment with SNS-B29/UU began when the tumours reached an
approximate size of 20 to 40 mm.sup.3 (approximately 4 weeks after
tumour cell injection). Treatment with SNS01 began when the tumours
reached an approximate size of 130 mm.sup.3 (approximately 6 weeks
after tumour cell injection). Mice received the test article
twice-weekly via tail vein intra-venous injection.
TABLE-US-00018 STUDY ID: EX9 No. Dose Total # Animals Test N/P
level Injection injec- Group (female) Article ratio (mg/kg) Volume
tions Ex9-G1 3 Control.sup.a 6 1.5 mg/kg 0.1 mL 11 Ex9-G2 4 SNS- 6
1.5 mg/kg 0.1 mL 11 B29/UU Ex9-G3 4 SNS- 6 0.75 mg/kg 0.05 mL 11
B29/UU Ex9-G4 4 SNS- 6 0.38 mg/kg 0.025 mL 11 B29/UU Ex9-G5 3 SNS-
6 0.15 mg/kg 0.01 mL 11 B29/UU Ex9-G9 3 SNS01 6 1.5 mg/kg 0.1 mL 7
.sup.aPEI complex containing a non-expressing plasmid (same vector
background as pExp5A) and a non-targeting siRNA
Repeated Dose Tumour Study
[0217] The repeated dose tumour study was designed to determine the
minimum effective therapeutic dose of SNS-B29/UU and to confirm
that the GLP-grade SNS01 test article retained the tumour
inhibition activity demonstrated by the research-grade test article
SNS-B29/UU. A secondary objective was to assess any toxic effects
of the treatment by monitoring the treated mice for clinical signs,
body weight, and organ weight. Test article therapeutic
anti-tumoural activity was monitored by twice-weekly tumour volume
measurements using digital calipers. Upon sacrifice the tumours
were excised and weighed.
[0218] All the mice survived to the scheduled sacrifice date.
Control mice that were treated with PEI nanocomplexes containing a
non-expressing plasmid and a non-targeting siRNA had an average
tumour volume of 284 mm.sup.3 at the time of sacrifice while mice
treated with 1.5 mg/kg SNS-B29/UU had an average tumour volume of
only 13 mm.sup.3, a 95% (*p=0.026) reduction in tumour growth.
However, when it was attempted to excise the tumours from mice that
had been treated with 1.5 mg/kg SNS-B29/UU, no evidence of a tumour
was found in any of the mice. Decreasing the dose of SNS-B29/UU by
half to 0.75 mg/kg still resulted in a 91% (*p=0.03) and 87%
(*p=0.04) decrease in tumour volume and weight, respectively, and
in one mouse the tumour had completely disappeared. Therefore, the
optimum therapeutic dose for twice-weekly injections of SNS-B29/UU
appears to be between 0.75 mg/kg and 1.5 mg/kg. Twice-weekly doses
of SNS-B29/UU doses as low as 0.15 mg/kg still resulted in a 60%
reduction in the final tumour volume indicating that SNS-B29/UU has
potent anti-tumoural activity over a wide dose range.
[0219] In addition to inhibiting tumour growth, treatment with
SNS-B29/UU and SNS01 at 0.75 mg/kg and 1.5 mg/kg resulted in
significant reduction in tumour volume indicating that this
treatment is capable of inducing tumour regression, likely through
the induction of apoptosis in the tumour. The percent change in
tumour volume in tumour-bearing mice treated with SNS-B29/UU, at
dose levels of 0.75 mg/kg and 1.5 mg/kg, was -244% and -245%,
respectively. The tumours of control mice increased in size by more
than 2000% during the same time period. Twice-weekly injections of
SNS01 also significantly shrunk multiple myeloma tumours. The
percent change in tumour volume for mice treated with 1.5 mg/kg
SNS01 was -349%, indicating that SNS01 is just as effective as
SNS-B29/UU. The use of GLP-grade materials may in fact have
increased the biological activity since treatment with SNS01
achieved a 349% decrease in tumour volume following only 25 days of
treatment while SNS-B29/UU achieved a 245% reduction in tumour
volume following 35 days of treatment. In addition, the tumours
treated with SNS01 were quite large (.about.130 mm.sup.3)
indicating that treatment with SNS01 is effective against
well-established tumours.
[0220] The treatment was well tolerated by all mice and no clinical
signs of toxicity were observed. The mice in all groups continued
to gain weight throughout the study. No changes in the macroscopic
appearance of the organs was observed at necropsy and no
significant changes in the organ weight to body weight ratios
occurred.
[0221] Therefore SNS01 (and its preclinical version SNS-B29/UU) is
well tolerated by SCID mice and is extremely effective in treating
subcutaneous human multiple myeloma tumours when delivered by
intra-venous injection twice per week. All doses of SNS-B29/UU that
were tested were effective at inhibiting tumour growth but the
highest dose of 1.5 mg/kg successfully eliminated tumours in all
mice receiving treatment.
Example 22
Biodistribution of Plasmid DNA and siRNA Polyethylenimine (JetPEI)
Complexes
[0222] Green fluorescent protein ("GFP") GFP-expression constructs
were used to determine localization of plasmid DNA delivered by PEI
complexes. Two promoters were used to drive GFP expression: EF1:
ubiquitous promoter (EF1::GFP) or B29: B-cell specific promoter
(B29::GFP). PEI complexes containing 20 micrograms of GFP plasmid
DNA and 10 micrograms of a fluorescently-labelled (DY547) h5A1
siRNA were prepared at an N/P ratio of 6. BalB/C mice were injected
intra-venously with either 5% glucose or PEI complexes on two
consecutive days. Seventy-two hours following the firsts injection
the mice were euthanized and their organs were harvested and
analyzed for GFP expression and DY547-siRNA by confocal
microscopy.
Bone Marrow:
[0223] In most cases there was evidence of DY547-siRNA but no GFP
expression. Timing of organ harvest may not coincide with peak
expression of GFP; and there may be quenching of GFP signal or GFP
may not be expressed. However, GFP and DY547 that colocalized to
the same bone marrow cells in some instances was observed.
Therefore, this provides evidence that PEI nanoparticles can
transfect bone marrow cells in a live animal when given by
intra-venous injection
Lung:
[0224] In most cases there was evidence of DY547-siRNA but no GFP
expression. Timing of organ harvest may not coincide with peak
expression of GFP or there may be quenching of GFP signal or GFP
may not be expressed.
Spleen:
[0225] Evidence of GFP expression (when driven by EF1 promoter)
colocalizing in cells also positive for the presence of DY547-siRNA
was seen. Expression of GFP was much lower in spleen cells when
driven by the B29 promoter. This shows that PEI nanoparticles
appear to transfect cells of the spleen.
Kidney:
[0226] No GFP or DY547 was observed indicating nanoparticles may
not enter kidney.
Liver:
[0227] In most cases there was evidence of DY547-siRNA but no GFP
expression. This provides evidence that PEI nanoparticles are
transfecting cells of the liver.
Heart:
[0228] Colocalization of EF1::GFP and DY547-siRNA in tissue of
heart was seen, thus indicating that PEI nanoparticles may be
transfecting this organ. No GFP was observed with B29 promoter.
Example 23
Effect of DNA:siRNA Ratio on HA-eIF5A.sup.K50R Expression
[0229] KAS cells were transfected with nanoparticles containing
B29-HA-eIF5A.sup.K50R (plasmid driven by B-cell-specific promoter)
and h5A1 siRNA. JET PEI.TM. nanoparticles containing different
ratios of pExp5A and h5A1 siRNA were made and incubated for 4 hours
at room temperature prior to addition to KAS cells. Four hours
after transfection, the nanoparticle-containing media was replaced
with fresh media. Twenty-four hours later the cell lysate was
harvested and used for western blot analysis with an antibody
against HA. The ratio of DNA:siRNA was varied from the standard
ratio of 2:1. The accumulation of HA-eIF5A.sup.K50R peaked at
ratios of 1:0, 3:1, and 2:1. See FIG. 30.
Example 24
Effect of DNA:siRNA Ratio on Apoptosis Induced by Nanoparticle
Transfection
[0230] Nanoparticles containing different ratios of pExp5A and h5A1
siRNA were made and incubated for 4 hours at room temperature prior
to addition to KAS cells. Four hours after transfection, the
nanoparticle-containing media was replaced with fresh media.
Forty-eight hours later the cells were harvested, labelled with
Annexin V/PI and analyzed by FACS. The induction of apoptosis was
highest in cells transfected with nanoparticles with the standard
DNA:siRNA ratio of 2:1. See FIG. 31.
Example 25
Administration of PEI Complexes (N/P=6 or 8) Containing eIF5A1K50R
Plasmid and eIF5A1 siRNA (siSTABLE or Non-siSTABLE) Inhibits Growth
of Multiple Myeloma Subcutaneous Tumours and Results in Tumour
Shrinkage
[0231] SCID mice were injected subcutaneously with KAS cells.
Treatment was initiated when palpable tumours were observed. Mice
were injected intra-venously 2 times per week with either: (G1) PEI
complexes containing 20 mg of pCpG-mcs (empty vector) and 10 mg of
control siRNA at N/P=8 (medium dose); (G5) PEI complexes containing
20 mg of the RNAi-resistant plasmid pCpG-eIF5A1k50R and 10 mg of
siSTABLE h5A 1 siRNA at N/P=8 (Imedium dose, siSTABLE); (G8) PEI
complexes containing 20 mg of the RNAi-resistant plasmid
pCpG-eIF5A1k50R and 10 mg of h5A1 siRNA at N/P=6 (medium dose,
N/P=6). The data shown is the individual tumour volume for the mice
in each group. The final injection was given at day 40 after
initiation of treatment. See FIG. 32.
Example 26
JET PEI.TM. Nanoparticles are being Effectively Taken Up by Tumour
Tissue and that Nanoparticles are Delivering Plasmid and siRNA to
the Same Cell
[0232] Tumour section 48 hours after injection with nanoparticles
containing pExp-GFP (GFP under control of B-cell-specific promoter)
and DY547-siRNA (fluorescently-labelled siRNA). Co-localized
expression of GFP and DY547 is observed in tumour section following
confocal microscopy indicating that the nanoparticles are being
effectively taken up by tumour tissue and that nanoparticles are
delivering plasmid and siRNA to the same cell. See FIG. 33.
Sequence CWU 1
1
34121DNAHomo sapiens 1aagctggact cctcctacac a 21221DNAHomo sapiens
2aaaggaatga cttccagctg a 21321DNAArtificial SequenceDescription of
Combined DNA/RNA Molecule Synthetic oligonucleotide 3acacauccuc
cucaggucgt t 21421DNAArtificial SequenceDescription of Combined
DNA/RNA Molecule Synthetic oligonucleotide 4cgaccugagg aggaugugut t
21521RNAHomo sapiens 5gcuggacucc uccuacacau u 216154PRTHomo sapiens
6Met Ala Asp Asp Leu Asp Phe Glu Thr Gly Asp Ala Gly Ala Ser Ala 1
5 10 15 Thr Phe Pro Met Gln Cys Ser Ala Leu Arg Lys Asn Gly Phe Val
Val 20 25 30 Leu Lys Gly Arg Pro Cys Lys Ile Val Glu Met Ser Thr
Ser Lys Thr 35 40 45 Gly Arg His Gly His Ala Lys Val His Leu Val
Gly Ile Asp Ile Phe 50 55 60 Thr Gly Lys Lys Tyr Glu Asp Ile Cys
Pro Ser Thr His Asn Met Asp 65 70 75 80 Val Pro Asn Ile Lys Arg Asn
Asp Phe Gln Leu Ile Gly Ile Gln Asp 85 90 95 Gly Tyr Leu Ser Leu
Leu Gln Asp Ser Gly Glu Val Arg Glu Asp Leu 100 105 110 Arg Leu Pro
Glu Gly Asp Leu Gly Lys Glu Ile Glu Gln Lys Tyr Asp 115 120 125 Cys
Gly Glu Glu Ile Leu Ile Thr Val Leu Ser Ala Met Thr Glu Glu 130 135
140 Ala Ala Val Ala Ile Lys Ala Met Ala Lys 145 150
719DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 7cagcaaggga gcacctatg 19819DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
8gttgcagtga gcggagatg 199297DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 9accaccctgg gccaggctgg
gccaagccag gcggcccctg tgttttcccc agtctctggg 60ctgctggagg gaaccaggtt
gttttggcat cagcctctac tgagccggag cccttccttt 120cctgctgctt
tgcatagtgg cactaattcc gtcctcctac ctccaccagg gacctaggca
180gccgggtaga tggtgggagg aggcttcact tctcccccaa gcagggtctc
cacctgcttg 240aggctgccct gggttggggg aggccttggc tttacctaaa
gactttttaa cacctct 29710800DNAHomo sapiens 10gggaacagct gccagctggg
agaccaagtg caatcaacct gcacgtgcaa agcctccctc 60ccaagccagg ctgtgctcca
cttcctgttg accctggagg gaatccttcg aggcccctct 120gctattcctg
ctctgaattc cagcaaggga gcacctatgc tgtgggagct gccagtttaa
180ctggggaatc aagaccagca caggggaact agtgagaaca gtgccaattt
tcaccagatt 240ccctctggaa ttccaggtgg ggcaggtggg taaggccccc
acgcctgcag tttcaggtaa 300atctctccac caccctgggc caggctgggc
caagccaggc ggcccctgtg ttttccccag 360tctctgggct gctggaggga
accaggttgt tttggcatca gcctctactg agccggagcc 420cttcctttcc
tgctgctttg catagtggca ctaattccgt cctcctacct ccaccaggga
480cctaggcagc cgggtagatg gtgggaggag gcttcacttc tcccccaagc
agggtctcca 540cctgcttgag gctgccctgg gttgggggag gccttggctt
tacctaaaga ctttttaaca 600cctctgaaca acacagtttc cctgagactt
tgaagctctt gttttattta tttatttatt 660tatttattta cttatttatt
tatttgcaga cagagtctca ctctgttgcc cagactggag 720tgcagtggca
ccatctccgc tcactgcaac ctccgtctcc tgagttcaag caattctcct
780gcctcagcct ccaaagtacc 8001128DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 11ccaactagtg cgaccgccaa
accttagc 281231DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 12caaaagcttg acaacgtccg aggctccttg g
3113188DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 13gcgaccgcca aaccttagcg gcccagctga
caaaagcctg ccctccccca gggtccccgg 60agagctggtg cctcccctgg gtcccaattt
gcatggcagg aaggggcctg gtgaggaaga 120ggcggggagg ggacaggctg
cagccggtgc agttacacgt tttcctccaa ggagcctcgg 180acgttgtc
188141237DNAHomo sapiens 14cctgcagggc ccactagtaa acggagggtt
gtgaggagag tgagaggtgg acagagggca 60ccgacgattt agcatctctt cctctcctgg
gggtcgagga tgagagacaa aaaagaagct 120gccaggaaac ataaaattca
gagggctcag ctgcagggct gaggtctgca agcatgctgt 180gtacacttgt
gcatgttgtg ccctgcacaa gggcatctct gaaggggctg cactggaccc
240aggggcaggg gcgcaaaggt gagtttatat cagttcctga gcactgtggc
tccatccagc 300actctgagga caggcaggat acagctggag gacctgaggg
ctcccccaca ccagctcctg 360ttccctgccc aagaccccct ggacctgcag
acaacaattc aacgcactca gagtcccaca 420gttaagaact ccctgaagaa
gcccccagtg gctgcgtggt ggattttcgc aaagctgtct 480ccacctacat
ccaccctgtt tggcagcccc tacatactct ttcacagcat gaggaaggga
540ggcctctcac caagacctgg actgaatctt ctcccagtgg ctgccacacc
tgacctgctc 600ttgctccaga acctctgtgg ctcccatcct ccacagggtc
aacttccaac atggctgcct 660gcactccagc caagaggctc tgctctgggc
ccctccagat gcctgacctg ggtctgtggc 720tgccctgtcc ttcttcagtg
ctcctcttcc cgctgggtga ggaatagttc aggacagagg 780agctaagttc
aggttcattc ataggacagg tgcctatttc gctcacggcc caggaataga
840gacttgccgg gctcggccct tcggggagtt ggcagacggc agaggggagg
ctggctggcc 900caggggatga ccaccggtgg ggtaagcaca gacagagggg
agcacaggct tcccccagaa 960gactgagagg ccccccagag gcatccacag
aggaccccag ctgtgctgcc caagctgggc 1020gaccgccaaa ccttagcggc
ccagctgaca aaagcctgcc ctcccccagg gtccccggag 1080agctggtgcc
tcccctgggt cccaatttgc atggcaggaa ggggcctggt gaggaagagg
1140cggggagggg acaggctgca gccggtgcag ttacacgttt tcctccaagg
agcctcggac 1200gttgtcacgg gtttggggtc ggggacagag cggtgac
12371561DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 15cgccatggac atgtaccctt acgacgtccc agactacgct
gcagatgatt tggacttcga 60g 611628DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 16cgcgctagcc agttattttg
ccatcgcc 2817497DNAArtificial SequenceDescription of Artificial
Sequence Synthetic polynucleotide 17acatgtaccc ttacgacgtc
ccagactacg ctgcagatga tttggacttc gagacaggag 60atgcaggggc ctcagccacc
ttcccaatgc agtgctcagc attacgtaag aatggttttg 120tggtgctcaa
gggccggcca tgtaagatcg tcgagatgtc tacttcgaag actggcaggc
180atggccatgc caaggtccat ctggttggca ttgatatttt tactgggaag
aaatatgaag 240atatctgccc gtcgactcat aacatggatg tccccaacat
caaaaggaat gatttccagc 300tgattggcat ccaggatggg tacctatccc
tgctccagga cagtggggag gtacgagagg 360accttcgtct gcctgaggga
gaccttggca aggagattga gcagaagtat gactgtggag 420aagagatcct
gatcacagtg ctgtccgcca tgacagagga ggcagctgtt gcaatcaagg
480cgatggcaaa ataactg 49718165PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 18Met Asp Met Tyr Pro Tyr
Asp Val Pro Asp Tyr Ala Ala Asp Asp Leu 1 5 10 15 Asp Phe Glu Thr
Gly Asp Ala Gly Ala Ser Ala Thr Phe Pro Met Gln 20 25 30 Cys Ser
Ala Leu Arg Lys Asn Gly Phe Val Val Leu Lys Gly Arg Pro 35 40 45
Cys Lys Ile Val Glu Met Ser Thr Ser Lys Thr Gly Arg His Gly His 50
55 60 Ala Lys Val His Leu Val Gly Ile Asp Ile Phe Thr Gly Lys Lys
Tyr 65 70 75 80 Glu Asp Ile Cys Pro Ser Thr His Asn Met Asp Val Pro
Asn Ile Lys 85 90 95 Arg Asn Asp Phe Gln Leu Ile Gly Ile Gln Asp
Gly Tyr Leu Ser Leu 100 105 110 Leu Gln Asp Ser Gly Glu Val Arg Glu
Asp Leu Arg Leu Pro Glu Gly 115 120 125 Asp Leu Gly Lys Glu Ile Glu
Gln Lys Tyr Asp Cys Gly Glu Glu Ile 130 135 140 Leu Ile Thr Val Leu
Ser Ala Met Thr Glu Glu Ala Ala Val Ala Ile 145 150 155 160 Lys Ala
Met Ala Lys 165 19154PRTHomo sapiens 19Met Ala Asp Asp Leu Asp Phe
Glu Thr Gly Asp Ala Gly Ala Ser Ala 1 5 10 15 Thr Phe Pro Met Gln
Cys Ser Ala Leu Arg Lys Asn Gly Phe Val Val 20 25 30 Leu Lys Gly
Arg Pro Cys Lys Ile Val Glu Met Ser Thr Ser Lys Thr 35 40 45 Gly
Lys His Gly His Ala Lys Val His Leu Val Gly Ile Asp Ile Phe 50 55
60 Thr Gly Lys Lys Tyr Glu Asp Ile Cys Pro Ser Thr His Asn Met Asp
65 70 75 80 Val Pro Asn Ile Lys Arg Asn Asp Phe Gln Leu Ile Gly Ile
Gln Asp 85 90 95 Gly Tyr Leu Ser Leu Leu Gln Asp Ser Gly Glu Val
Arg Glu Asp Leu 100 105 110 Arg Leu Pro Glu Gly Asp Leu Gly Lys Glu
Ile Glu Gln Lys Tyr Asp 115 120 125 Cys Gly Glu Glu Ile Leu Ile Thr
Val Leu Ser Ala Met Thr Glu Glu 130 135 140 Ala Ala Val Ala Ile Lys
Ala Met Ala Lys 145 150 2036DNAArtificial SequenceDescription of
Artificial Sequence Synthetic oligonucleotide 20aattctcgag
tcatcgataa gcggccgcag acgcgt 362136DNAArtificial
SequenceDescription of Artificial Sequence Synthetic
oligonucleotide 21aattacgcgt ctgcggccgc ttatcgatga ctcgag
36221030DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 22ggcatgtgaa ctggctgtct tggttttcat
ctgtacttca tctgctacct ctgtgacctg 60aaacatattt ataattccat taagctgtgc
atatgataga tttatcatat gtattttcct 120taaaggattt ttgtaagaac
taattgaatt gatacctgta aagtctttat cacactaccc 180aataaataat
aaatctcttt gttcagctct ctgtttctat aaatatgtac aagttttatt
240gtttttagtg gtagtgattt tattctcttt ctatatatat acacacacat
gtgtgcattc 300ataaatatat acaattttta tgaataaaaa attattagca
atcaatattg aaaaccactg 360atttttgttt atgtgagcaa acagcagatt
aaaaggaatt ctcgagtcat cgataagcgg 420ccgcagacgc gtaattcagt
caatatgttc accccaaaaa agctgtttgt taacttgcca 480acctcattct
aaaatgtata tagaagccca aaagacaata acaaaaatat tcttgtagaa
540caaaatggga aagaatgttc cactaaatat caagatttag agcaaagcat
gagatgtgtg 600gggatagaca gtgaggctga taaaatagag tagagctcag
aaacagaccc attgatatat 660gtaagtgacc tatgaaaaaa atatggcatt
ttacaatggg aaaatgatga tctttttctt 720ttttagaaaa acagggaaat
atatttatat gtaaaaaata aaagggaacc catatgtcat 780accatacaca
caaaaaaaat tccagtgaat tataagtcta aatggagaag gcaaaacttt
840aaatctttta gaaaataata tagaagcatg ccatcaagac ttcagtgtag
agaaaaattt 900cttatgactc aaagtcctaa ccacaaagaa aagattgtta
attagattgc atgaatatta 960agacttattt ttaaaattaa aaaaccatta
agaaaagtca ggccatagaa tgacagaaaa 1020tatttgcaac
10302331DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 23gaagcggccg caccaccctg ggccaggctg g
312436DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 24ccacgcgtag aggtgttaaa aagtctttag gtaaag
36252282DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 25ttaattaaaa ttatctctaa ggcatgtgaa
ctggctgtct tggttttcat ctgtacttca 60tctgctacct ctgtgacctg aaacatattt
ataattccat taagctgtgc atatgataga 120tttatcatat gtattttcct
taaaggattt ttgtaagaac taattgaatt gatacctgta 180aagtctttat
cacactaccc aataaataat aaatctcttt gttcagctct ctgtttctat
240aaatatgtac aagttttatt gtttttagtg gtagtgattt tattctcttt
ctatatatat 300acacacacat gtgtgcattc ataaatatat acaattttta
tgaataaaaa attattagca 360atcaatattg aaaaccactg atttttgttt
atgtgagcaa acagcagatt aaaaggaatt 420ctcgagtcat cgataagcgg
ccgcaccacc ctgggccagg ctgggccaag ccaggcggcc 480cctgtgtttt
ccccagtctc tgggctgctg gagggaacca ggttgttttg gcatcagcct
540ctactgagcc ggagcccttc ctttcctgct gctttgcata gtggcactaa
ttccgtcctc 600ctacctccac cagggaccta ggcagccggg tagatggtgg
gaggaggctt cacttctccc 660ccaagcaggg tctccacctg cttgaggctg
ccctgggttg ggggaggcct tggctttacc 720taaagacttt ttaacacctc
tacgcgtaat tcagtcaata tgttcacccc aaaaaagctg 780tttgttaact
tgccaacctc attctaaaat gtatatagaa gcccaaaaga caataacaaa
840aatattcttg tagaacaaaa tgggaaagaa tgttccacta aatatcaaga
tttagagcaa 900agcatgagat gtgtggggat agacagtgag gctgataaaa
tagagtagag ctcagaaaca 960gacccattga tatatgtaag tgacctatga
aaaaaatatg gcattttaca atgggaaaat 1020gatgatcttt ttctttttta
gaaaaacagg gaaatatatt tatatgtaaa aaataaaagg 1080gaacccatat
gtcataccat acacacaaaa aaattccagt gaattataag tctaaatgga
1140gaaggcaaaa ctttaaatct tttagaaaat aatatagaag catgccatca
agacttcagt 1200gtagagaaaa atttcttatg actcaaagtc ctaaccacaa
agaaaagatt gttaattaga 1260ttgcatgaat attaagactt atttttaaaa
ttaaaaaacc attaagaaaa gtcaggccat 1320agaatgacag aaaatatttg
caacacccca gtaaagagaa ttgtaatatg cagattataa 1380aaagaagtct
tacaaatcag taaaaaataa aactagacaa aaatttgaac agatgaaaga
1440gaaactctaa ataatcatta cacatgagaa actcaatctc agaaatcaga
gaactatcat 1500tgcatataca ctaaattaga gaaatattaa aaggctaagt
aacatctgtg gcttaattaa 1560aacaggtagt tgacaattaa acattggcat
agtatatctg catagtataa tacaactcac 1620tataggaggg ccatcatggc
caagttgacc agtgctgtcc cagtgctcac agccagggat 1680gtggctggag
ctgttgagtt ctggactgac aggttggggt tctccagaga ttttgtggag
1740gatgactttg caggtgtggt cagagatgat gtcaccctgt tcatctcagc
agtccaggac 1800caggtggtgc ctgacaacac cctggcttgg gtgtgggtga
gaggactgga tgagctgtat 1860gctgagtgga gtgaggtggt ctccaccaac
ttcagggatg ccagtggccc tgccatgaca 1920gagattggag agcagccctg
ggggagagag tttgccctga gagacccagc aggcaactgt 1980gtgcactttg
tggcagagga gcaggactga ggataaccta ggaaacctta aaacctttaa
2040aagccttata tattcttttt tttcttataa aacttaaaac cttagaggct
atttaagttg 2100ctgatttata ttaattttat tgttcaaaca tgagagctta
gtacatgaaa catgagagct 2160tagtacatta gccatgagag cttagtacat
tagccatgag ggtttagttc attaaacatg 2220agagcttagt acattaaaca
tgagagctta gtacatacta tcaacaggtt gaactgctga 2280tc
22822629DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 26gttatcgata ctagtgcgac cgccaaacc
292736DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 27caagcggccg ccataccaca tttgtagagg ttttac
362825DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 28caccatggca gatgatttgg acttc 2529154PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
29Met Ala Asp Asp Leu Asp Phe Glu Thr Gly Asp Ala Gly Ala Ser Ala 1
5 10 15 Thr Phe Pro Met Gln Cys Ser Ala Leu Arg Lys Asn Gly Phe Val
Val 20 25 30 Leu Lys Gly Arg Pro Cys Lys Ile Val Glu Met Ser Thr
Ser Lys Thr 35 40 45 Gly Lys His Gly His Ala Lys Val His Leu Val
Gly Ile Asp Ile Phe 50 55 60 Thr Gly Lys Lys Tyr Glu Asp Ile Cys
Pro Ser Thr His Asn Met Asp 65 70 75 80 Val Pro Asn Ile Lys Arg Asn
Asp Phe Gln Leu Ile Gly Ile Gln Asp 85 90 95 Gly Tyr Leu Ser Leu
Leu Gln Asp Ser Gly Glu Val Arg Glu Asp Leu 100 105 110 Arg Leu Pro
Glu Gly Asp Leu Gly Lys Glu Ile Glu Gln Lys Tyr Asp 115 120 125 Cys
Gly Glu Glu Ile Leu Ile Thr Val Leu Ser Ala Met Thr Glu Glu 130 135
140 Ala Ala Val Ala Ile Lys Ala Met Ala Lys 145 150
303370DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 30ttaattaaaa ttatctctaa ggcatgtgaa
ctggctgtct tggttttcat ctgtacttca 60tctgctacct ctgtgacctg aaacatattt
ataattccat taagctgtgc atatgataga 120tttatcatat gtattttcct
taaaggattt ttgtaagaac taattgaatt gatacctgta 180aagtctttat
cacactaccc aataaataat aaatctcttt gttcagctct ctgtttctat
240aaatatgtac aagttttatt gtttttagtg gtagtgattt tattctcttt
ctatatatat 300acacacacat gtgtgcattc ataaatatat acaattttta
tgaataaaaa attattagca 360atcaatattg aaaaccactg atttttgttt
atgtgagcaa acagcagatt aaaaggaatt 420ctcgagtcat cgatactagt
gcgaccgcca aaccttagcg gcccagctga caaaagcctg 480ccctccccca
gggtccccgg agagctggtg cctcccctgg gtcccaattt gcatggcagg
540aaggggcctg gtgaggaaga ggcggggagg ggacaggctg cagccggtgc
agttacacgt 600tttcctccaa ggagcctcgg acgttgtcaa gcttctgcct
tctccctcct gtgagtttgg 660taagtcactg actgtctatg cctgggaaag
ggtgggcagg agatggggca gtgcaggaaa 720agtggcacta tgaaccctgc
agccctagga atgcatctag acaattgtac taaccttctt 780ctctttcctc
tcctgacagg ttggtgtaca gtagcttcca ccatggcaga tgatttggac
840ttcgagacag gagatgcagg ggcctcagcc accttcccaa tgcagtgctc
agcattacgt 900aagaatggtt ttgtggtgct caagggccgg ccatgtaaga
tcgtcgagat gtctacttcg 960aagactggca ggcatggcca tgccaaggtc
catctggttg gtattgatat ttttactggg 1020aagaaatatg aagatatctg
cccgtcgact cataacatgg atgtccccaa catcaaaagg 1080aatgatttcc
agctgattgg catccaggat gggtacctat ccctgctcca ggacagtggg
1140gaggtacgag aggaccttcg tctgcctgag ggagaccttg gcaaggagat
tgagcagaag 1200tatgactgtg gagaagagat cctgatcaca gtgctgtccg
ccatgacaga ggaggcagct 1260gttgcaatca
aggcgatggc aaaataactg gctagctggc cagacatgat aagatacatt
1320gatgagtttg gacaaaccac aactagaatg cagtgaaaaa aatgctttat
ttgtgaaatt 1380tgtgatgcta ttgctttatt tgtaaccatt ataagctgca
ataaacaagt taacaacaac 1440aattgcattc attttatgtt tcaggttcag
ggggaggtgt gggaggtttt ttaaagcaag 1500taaaacctct acaaatgtgg
tatggcggcc gcaccaccct gggccaggct gggccaagcc 1560aggcggcccc
tgtgttttcc ccagtctctg ggctgctgga gggaaccagg ttgttttggc
1620atcagcctct actgagccgg agcccttcct ttcctgctgc tttgcatagt
ggcactaatt 1680ccgtcctcct acctccacca gggacctagg cagccgggta
gatggtggga ggaggcttca 1740cttctccccc aagcagggtc tccacctgct
tgaggctgcc ctgggttggg ggaggccttg 1800gctttaccta aagacttttt
aacacctcta cgcgtaattc agtcaatatg ttcaccccaa 1860aaaagctgtt
tgttaacttg ccaacctcat tctaaaatgt atatagaagc ccaaaagaca
1920ataacaaaaa tattcttgta gaacaaaatg ggaaagaatg ttccactaaa
tatcaagatt 1980tagagcaaag catgagatgt gtggggatag acagtgaggc
tgataaaata gagtagagct 2040cagaaacaga cccattgata tatgtaagtg
acctatgaaa aaaatatggc attttacaat 2100gggaaaatga tgatcttttt
cttttttaga aaaacaggga aatatattta tatgtaaaaa 2160ataaaaggga
acccatatgt cataccatac acacaaaaaa attccagtga attataagtc
2220taaatggaga aggcaaaact ttaaatcttt tagaaaataa tatagaagca
tgccatcaag 2280acttcagtgt agagaaaaat ttcttatgac tcaaagtcct
aaccacaaag aaaagattgt 2340taattagatt gcatgaatat taagacttat
ttttaaaatt aaaaaaccat taagaaaagt 2400caggccatag aatgacagaa
aatatttgca acaccccagt aaagagaatt gtaatatgca 2460gattataaaa
agaagtctta caaatcagta aaaaataaaa ctagacaaaa atttgaacag
2520atgaaagaga aactctaaat aatcattaca catgagaaac tcaatctcag
aaatcagaga 2580actatcattg catatacact aaattagaga aatattaaaa
ggctaagtaa catctgtggc 2640ttaattaaaa caggtagttg acaattaaac
attggcatag tatatctgca tagtataata 2700caactcacta taggagggcc
atcatggcca agttgaccag tgctgtccca gtgctcacag 2760ccagggatgt
ggctggagct gttgagttct ggactgacag gttggggttc tccagagatt
2820ttgtggagga tgactttgca ggtgtggtca gagatgatgt caccctgttc
atctcagcag 2880tccaggacca ggtggtgcct gacaacaccc tggcttgggt
gtgggtgaga ggactggatg 2940agctgtatgc tgagtggagt gaggtggtct
ccaccaactt cagggatgcc agtggccctg 3000ccatgacaga gattggagag
cagccctggg ggagagagtt tgccctgaga gacccagcag 3060gcaactgtgt
gcactttgtg gcagaggagc aggactgagg ataacctagg aaaccttaaa
3120acctttaaaa gccttatata ttcttttttt tcttataaaa cttaaaacct
tagaggctat 3180ttaagttgct gatttatatt aattttattg ttcaaacatg
agagcttagt acatgaaaca 3240tgagagctta gtacattagc catgagagct
tagtacatta gccatgaggg tttagttcat 3300taaacatgag agcttagtac
attaaacatg agagcttagt acatactatc aacaggttga 3360actgctgatc
33703121DNAArtificial SequenceDescription of Combined DNA/RNA
Molecule Synthetic oligonucleotide 31gcuggacucc uccuacacat t
213221DNAArtificial SequenceDescription of Combined DNA/RNA
Molecule Synthetic oligonucleotide 32uguguaggag gaguccagct t
2133537DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 33atagggagac ccaagctgga gaccatgtac
ccatacgacg tcccagacta cgctggaagc 60ttaatggcag atgatttgga cttcgagaca
ggagatgcag gggcctcagc caccttccca 120atgcagtgct cagcattacg
taagaatggt tttgtggtgc tcaagggccg gccatgtaag 180atcgtcgaga
tgtctacttc gaagactggc aggcatggcc atgccaaggt ccatctggtt
240ggtattgata tttttactgg gaagaaatat gaagatatct gcccgtcgac
tcataacatg 300gatgtcccca acatcaaaag gaatgatttc cagctgattg
gcatccagga tgggtaccta 360tccctgctcc aggacagtgg ggaggtacga
gaggaccttc gtctgcctga gggagacctt 420ggcaaggaga ttgagcagaa
gtatgactgt ggagaagaga tcctgatcac agtgctgtcc 480gccatgacag
aggaggcagc tgttgcaatc aaggccatgg caaaataact ggaattc
53734167PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 34Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly
Ser Leu Met Ala Asp 1 5 10 15 Asp Leu Asp Phe Glu Thr Gly Asp Ala
Gly Ala Ser Ala Thr Phe Pro 20 25 30 Met Gln Cys Ser Ala Leu Arg
Lys Asn Gly Phe Val Val Leu Lys Gly 35 40 45 Arg Pro Cys Lys Ile
Val Glu Met Ser Thr Ser Lys Thr Gly Arg His 50 55 60 Gly His Ala
Lys Val His Leu Val Gly Ile Asp Ile Phe Thr Gly Lys 65 70 75 80 Lys
Tyr Glu Asp Ile Cys Pro Ser Thr His Asn Met Asp Val Pro Asn 85 90
95 Ile Lys Arg Asn Asp Phe Gln Leu Ile Gly Ile Gln Asp Gly Tyr Leu
100 105 110 Ser Leu Leu Gln Asp Ser Gly Glu Val Arg Glu Asp Leu Arg
Leu Pro 115 120 125 Glu Gly Asp Leu Gly Lys Glu Ile Glu Gln Lys Tyr
Asp Cys Gly Glu 130 135 140 Glu Ile Leu Ile Thr Val Leu Ser Ala Met
Thr Glu Glu Ala Ala Val 145 150 155 160 Ala Ile Lys Ala Met Ala Lys
165
* * * * *